Descriptor: "MESH: Biopsy" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"MESH: Biopsy"' showing total 175 results

Start Over Descriptor "MESH: Biopsy"

175 results on '"MESH: Biopsy"'

51. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?]

Author: Cornec-Le Gall, Emilie, Le Meur, Yannick, Service de Nephrologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Immunologie et Pathologie (EA2216), and Université de Brest (UBO)-IFR148
Subjects: Receptors, Vasopressin, MESH: Mutation, MESH: Methylmalonic Acid, MESH: Hydroxocobalamin, MESH: Carrier Proteins, MESH: Lipotropic Agents, Models, Biological, Renin-Angiotensin System, MESH: Biopsy, Mice, MESH: Diagnosis, Differential, Animals, Humans, Multicenter Studies as Topic, MESH: Amino Acid Metabolism, Inborn Errors, MESH: Renal Dialysis, MESH: Homocysteine, MESH: Hypertension, Malignant, MESH: Treatment Outcome, Randomized Controlled Trials as Topic, MESH: Humans, MESH: Vitamin B Complex, MESH: Immunologic Factors, TOR Serine-Threonine Kinases, Disease Management, MESH: Adult, Epithelial Cells, MESH: Kidney, Drugs, Investigational, Benzazepines, Polycystic Kidney, Autosomal Dominant, MESH: Male, MESH: Recurrence, Disease Models, Animal, MESH: Kidney Function Tests, MESH: Antibodies, Monoclonal, Humanized, MESH: Methionine, MESH: Betaine, Tolvaptan, MESH: Drug Resistance, [SDV.IMM]Life Sciences [q-bio]/Immunology, Kidney Failure, Chronic, MESH: Leucovorin, MESH: Homocystinuria, Somatostatin, Antidiuretic Hormone Receptor Antagonists, Immunosuppressive Agents, Signal Transduction
Abstract: International audience; Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent Mendelian inherited disorder. It covers 6.1% of incident ESRD patients in France in 2011. Long left untreated, this disease will soon benefit from targeted therapies currently under evaluation. Several molecules have already reached the stage of clinical trials: the evaluation of mTOR inhibitors yielded deceiving results and, more recently, 2 different molecules demonstrated a slight impact on the progression of total kidney volume (TKV): tolvaptan, vasopressin receptor-V2 inhibitor and somatostatin analogues; both of these molecules acting throughout the decrease of intracellular AMPc. The purpose of this review is to briefly describe the signaling pathways involved, then to present both the published and ongoing clinical trials and the promising molecules evaluated in murine models.
Published: 2014

52. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency

Author: Yannick Le Meur, Emilie Cornec-Le Gall, Yahsou Delmas, Véronique Frémeaux-Bacchi, Laurent Doucet, Loïc De Parscau, Jean-François Benoist, Hélène Ogier, Service de Nephrologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Fibrose hépatique et cancer du foie, Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM), CHRU de Brest - Département de Pédiatrie (CHU BREST Pédiatrie), Réseau Maladies Métaboliques, Hôpitaux Universitaires du Grand Ouest, Service de Pédiatrie et Génétique Médicale, CHRU Brest - Laboratoire d'Anatomo-Pathologie (CHU - AnaPath), Comité d'Evaluation du Traitement pour les maladies de Niemann-Pick (CETNP), Société Française des Erreurs Innées du Métabolisme (SFEIM), Centre Référence des Maladies Héréditaires du Métabolisme [Paris-Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Service de neurologie, maladies métaboliques, Laboratoire de Biochimie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), LabEX IGO Immunothérapie Grand Ouest, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Service de Néphrologie, and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST )
Subjects: Male, Biopsy, MESH: Hydroxocobalamin, Drug Resistance, Leucovorin, Kidney, Kidney Function Tests, Gastroenterology, Hypertension, Malignant, chemistry.chemical_compound, MESH: Biopsy, Methionine, Recurrence, Hydroxocobalamin, MESH: Renal Dialysis, Homocysteine, MESH: Treatment Outcome, Lipotropic Agents, MESH: Immunologic Factors, Eculizumab, 3. Good health, Treatment Outcome, Hemolytic uremic syndrome (HUS), Nephrology, MESH: Kidney Function Tests, Vitamin B Complex, MESH: Betaine, MESH: Drug Resistance, [SDV.IMM]Life Sciences [q-bio]/Immunology, Homocystinuria, Oxidoreductases, MESH: Homocystinuria, medicine.drug, Adult, medicine.medical_specialty, Thrombotic microangiopathy, MESH: Mutation, MESH: Methylmalonic Acid, MESH: Carrier Proteins, Complement factor I, Antibodies, Monoclonal, Humanized, MESH: Lipotropic Agents, Cobalamin, Diagnosis, Differential, Renal Dialysis, MESH: Diagnosis, Differential, Internal medicine, Atypical hemolytic uremic syndrome, medicine, Humans, Immunologic Factors, MESH: Amino Acid Metabolism, Inborn Errors, MESH: Homocysteine, MESH: Hypertension, Malignant, Amino Acid Metabolism, Inborn Errors, MESH: Humans, MESH: Vitamin B Complex, business.industry, Vitamin B 12 Deficiency, MESH: Adult, MESH: Kidney, medicine.disease, MMACHC, MESH: Male, MESH: Recurrence, Betaine, Endocrinology, Methylmalonic aciduria, chemistry, MESH: Antibodies, Monoclonal, Humanized, MESH: Methionine, Mutation, Carrier Proteins, business, MESH: Leucovorin, Methylmalonic Acid
Abstract: International audience; A 20-year-old man was hospitalized for malignant hypertension, mechanical hemolysis, and kidney failure. Kidney biopsy confirmed glomerular and arteriolar thrombotic microangiopathy. Etiologic analyses, which included ADAMTS13 activity, stool culture, complement factor proteins (C3, C4, factor H, factor I, and MCP [membrane cofactor protein]), anti-factor H antibodies, HIV (human immunodeficiency virus) serology, and antinuclear and antiphospholipid antibodies, returned normal results. Malignant hypertension was diagnosed. Ten months later, we observed a relapse of acute kidney injury and mechanical hemolysis. Considering a diagnosis of complement dysregulation-related atypical hemolytic uremic syndrome (HUS), we began treatment with eculizumab. Despite the efficient complement blockade, the patient's kidney function continued to decline. We performed additional analyses and found that the patient's homocysteine levels were dramatically increased, with no vitamin B12 (cobalamin) or folate deficiencies. We observed very low plasma methionine levels associated with methylmalonic aciduria, which suggested cobalamin C disease. We stopped the eculizumab infusions and initiated specific treatment, which resulted in complete cessation of hemolysis. MMACHC (methylmalonic aciduria and homocystinuria type C protein) sequencing revealed compound heterozygosity for 2 causative mutations. To our knowledge, this is the first report of adult-onset cobalamin C-related HUS. Considering the wide availability and low cost of the homocysteine assay, we suggest that it be included in the diagnostic algorithm for adult patients who present with HUS.
Published: 2014

53. Central nervous system angiitis: a series of 31 patients

Author: David Saadoun, Du Le Thi Huong Boutin, Nathalie Costedoat-Chalumeau, Sophie Crozier, Karima Mokhtari, Patrice Cacoub, Yves Samson, Bertrand Wechsler, Guillaume Geri, Catherine Lubetzki, Zahir Amoura, Rémy Guillevin, Service de Réanimation polyvalente, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 (UPD5), Immunologie - Immunopathologie - Immunothérapie (I3), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Radiologie [Milétrie], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service des Urgences Cérébro-Vasculaires [Paris], CHU Pitié-Salpêtrière [APHP], Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Service de Neuropathologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne 2 [Pitié-Salpétrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Charles Foix - Jean Rostand-CHU Pitié-Salpêtrière [APHP]-Centre de référence des maladies autoimmunes et systémiques rares, Centre de référence des maladies autoimmunes et systémiques rares, Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière (NEMESIS-CRICM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Colliot, Olivier, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 ( UPD5 ), Immunologie - Immunopathologie - Immunothérapie ( I3 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Assistance publique - Hôpitaux de Paris (AP-HP)-IFR70-Hôpital de la Salpétrière, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière ( CRICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Centre d'Immunologie et de Maladies Infectieuses ( CIMI ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Charles Foix - Jean Rostand-CHU Pitié-Salpêtrière [APHP]-Centre de référence des maladies autoimmunes et systémiques rares, Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière ( NEMESIS-CRICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des Urgences Cérébro-Vasculaires [CHU Pitié-Salpétriêre], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Male, Pathology, MESH : Retrospective Studies, MESH: Cerebral Angiography, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Biopsy, MESH : Magnetic Resonance Angiography, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [INFO.INFO-IM] Computer Science [cs]/Medical Imaging, MESH: Magnetic Resonance Angiography, [ SPI.SIGNAL ] Engineering Sciences [physics]/Signal and Image processing, MESH : Vasculitis, Central Nervous System, [ INFO.INFO-CV ] Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], Gastroenterology, Magnetic resonance angiography, MESH : Paresis, MESH: Biopsy, [INFO.INFO-CV] Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], Risk Factors, MESH: Risk Factors, [ INFO.INFO-TI ] Computer Science [cs]/Image Processing, MESH : Female, MESH : Immunosuppressive Agents, CSF albumin, [ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imaging, MESH: Treatment Outcome, MESH: Middle Aged, medicine.diagnostic_test, [ INFO.INFO-IM ] Computer Science [cs]/Medical Imaging, Headache, General Medicine, Middle Aged, MESH : Adult, MESH : Risk Factors, 3. Good health, Paresis, Treatment Outcome, [INFO.INFO-TI] Computer Science [cs]/Image Processing [eess.IV], [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], Female, Steroids, MESH: Immunosuppressive Agents, Vasculitis, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Immunosuppressive Agents, Cerebral angiography, Adult, medicine.medical_specialty, MESH : Male, MESH : Treatment Outcome, MESH: Paresis, Rheumatology, Internal medicine, medicine, MESH : Cerebral Angiography, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, MESH : Middle Aged, Vasculitis, Central Nervous System, Retrospective Studies, [SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing, MESH : Headache, MESH: Humans, business.industry, MESH : Humans, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH: Headache, [INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], Retrospective cohort study, Magnetic resonance imaging, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH: Steroids, MESH: Male, Cerebral Angiography, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, MESH : Biopsy, business, MESH: Vasculitis, Central Nervous System, MESH: Female, Magnetic Resonance Angiography, MESH : Steroids
Abstract: International audience; Central nervous system (CNS) angiitis is a rare inflammatory disorder. To date, clinical data are lacking and treatment remains a matter of debate. The aim of this study is to analyse the main characteristics, response to therapy and outcome of 32 patients with CNS angiitis. Single-centre retrospective study in a tertiary centre was made. Diagnosis of CNS angiitis was made by cerebral angiography and/or magnetic resonance angiography and/or CNS biopsy. The main features and outcomes of primary and secondary CNS angiitis were compared and predictive factors of a favourable outcome were searched. Thirty-one patients (median age 45 Q1-Q3 37-54) sex ratio F/M 2.1) were included. Main clinical features were hemiparesis (35.5 %) and headache (29 %). The median CSF protein level was 0.64(0.52-0.81) g/L and was superior to 1 g/L in six cases. CNS magnetic resonance (MR) imaging findings were most frequently ischemic (96.8 %), bilateral (83.9 %), multiple (87.1 %) and supratentorial (96.8 %). The MR angiography was abnormal in all cases. Among the 31 patients in the study, 19 (61.3 %) were diagnosed with primary CNS angiitis. Systemic lupus erythematosus (n = 6) and vasculitis (n = 4) were the most frequent aetiologies of secondary CNS angiitis. No difference was evidenced between primary and secondary CNS angiitis. Steroids were administered in 79.2 % of treated patients and combined with immunosuppressants in 79.2 % of cases. Eight cases of CNS angiitis relapse were noted. CNS angiitis remains a severe illness. Treatment often associated steroids and immunosuppressants, and diagnosis delay is significantly associated with a poorer prognosis.
Published: 2013

54. Small airways diseases, excluding asthma and COPD: an overview

Author: Alain Didier, Christiane Knoop, Nicolas Roche, Thierry Chinet, Pascal Chanez, Arnaud Bourdin, Pierre-Régis Burgel, Daniel Dusser, Thierry Perez, Isabelle Tillie-Leblond, Marianne Kambouchner, Philippe Bonniaud, Antoine Deschildre, Jacques de Blic, Philippe Devillier, Anne Bergeron, François Laurent, Hilario Nunes, Jean-Charles Dalphin, Service de pneumologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de pneumologie [Saint-Louis], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de Pneumologie Allergologie [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service des maladies respiratoires [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service des Maladies Respiratoires [Marseille], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM], Service de pneumologie et oncologie thoracique [CHU Ambroise Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre Hospitalier Universitaire Ambroise Paré (CHU Ambroise Paré), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Foch [Suresnes], Unité de Biostatistique, Service de pédiatrie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Pneumologie-Allergologie, CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Service de chirurgie cardiovasculaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Recherches Sémiotiques (CeReS), Institut Sciences de l'Homme et de la Société (IR SHS UNILIM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service des maladies respiratoires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Avicenne-Jean Verdier-René Muret, LILLE - Service de Pneumologie (LILLE - Pneumo), Naval Research Laboratory (NRL), Service de Pneumo-Immuno-Allergologie, CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] ( PhyMedExp ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ) - Hôpital Nord [CHU - APHM], Laboratoire de Biologie et Pharmacologie des Epithéliums Respiratoires ( ILBPER ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Laboratoire Chrono-environnement - UFC (UMR 6249) ( LCE ), Université Bourgogne Franche-Comté [COMUE] ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Recherche Clinique, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Hôpital Foch [Suresnes], Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), CHU Toulouse [Toulouse]-Hôpital Larrey, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Centre de Recherches Sémiotiques ( CeReS ), Institut Sciences de l'Homme et de la Société ( IR SHS UNILIM ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Avicenne-Jean Verdier-René Muret, LILLE - Service de Pneumologie ( LILLE - Pneumo ), Naval Research Laboratory ( NRL ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biologie et Pharmacologie des Epithéliums Respiratoires (ILBPER), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Hôpital Foch [Suresnes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Avicenne-Jean Verdier-René Muret
Subjects: Constrictive bronchiolitis, medicine.medical_treatment, Biopsy, Immune deficiency, MESH: Respiratory Function Tests, Review, Pulmonary function testing, MESH: Biopsy, MESH: Lung Diseases, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH : Tomography, X-Ray Computed, MESH: Bronchography, MESH : Bronchography, COPD, Lung Diseases -- diagnosis -- etiology -- physiopathology, MESH : Prognosis, MESH : Lung Diseases, MESH : Bronchioles, respiratory system, Sciences bio-médicales et agricoles, Constrictive Bronchiolitis, Prognosis, Connective tissue disease, MESH : Risk Factors, MESH: Predictive Value of Tests, 3. Good health, Respiratory Function Tests, MESH: Bronchioles, 030220 oncology & carcinogenesis, MESH: Tomography, X-Ray Computed, constrictive bronchiolitis, Pulmonary and Respiratory Medicine, MESH: Prognosis, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, 03 medical and health sciences, Predictive Value of Tests, follicular bronchiolitis, medicine, MESH : Respiratory Function Tests, Lung transplantation, Humans, MESH : Predictive Value of Tests, Drug-induced lung disease, Asthma, lcsh:RC705-779, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, MESH: Humans, drug-induced lung disease, business.industry, Common variable immunodeficiency, Bronchography -- methods, MESH : Humans, Follicular bronchiolitis, lcsh:Diseases of the respiratory system, immune deficiency, medicine.disease, respiratory tract diseases, Airway pathology, 030228 respiratory system, connective tissue disease, MESH : Biopsy, Immunology, business, Tomography, X-Ray Computed, Diffuse panbronchiolitis, Bronchioles -- pathology -- physiopathology
Abstract: This review is the summary of a workshop on small airways disease, which took place in Porquerolles, France in November 2011. The purpose of this workshop was to review the evidence on small airways (bronchiolar) involvement under various pathophysiological circumstances, excluding asthma and chronic obstructive pulmonary disease. Histopathological patterns associated with small airways disease were reviewed, including cellular and obliterative bronchiolitis. Many pathophysiological conditions have been associated with small airways disease including airway infections, connective tissue diseases and inflammatory bowel diseases, bone marrow and lung transplantation, common variable immunodeficiency disorders, diffuse panbronchiolitis, and diseases related to environmental exposures to pollutants, allergens and drugs. Pathogenesis, clinical presentation, a computed tomography scan and pulmonary function test findings are reviewed, and therapeutic options are described with the objective of providing an integrative approach to these disorders., Congresses, SCOPUS: re.j, info:eu-repo/semantics/published
Published: 2013

55. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy

Author: Olivier Humbert, Alexandre Cochet, Salim Kanoun, Caroline Legouge, François Brunotte, Olivier Casasnovas, Inna Dygai-Cochet, Alina Berriolo-Riedinger, Michel Toubeau, Louis Berthet, Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Nucléaire, UNICANCER-UNICANCER, Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )
Subjects: MESH : Bone Marrow, Male, MESH : Retrospective Studies, Biopsy, MESH : Aged, Iliac crest, MESH : Lymphoma, Large B-Cell, Diffuse, Multimodal Imaging, 030218 nuclear medicine & medical imaging, [ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Biopsy, 0302 clinical medicine, International Prognostic Index, MESH: Aged, 80 and over, MESH: Fluorodeoxyglucose F18, Bone Marrow, MESH : Tomography, X-Ray Computed, MESH : Neoplasm Staging, MESH : Female, MESH: Aged, Aged, 80 and over, MESH : Prognosis, MESH: Middle Aged, medicine.diagnostic_test, MESH: Multimodal Imaging, MESH: Neoplasm Staging, MESH : Adult, Middle Aged, Prognosis, MESH: Positron-Emission Tomography, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH: Bone Marrow, Female, Radiology, Lymphoma, Large B-Cell, Diffuse, MESH: Tomography, X-Ray Computed, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Multimodal Imaging, MESH : Young Adult, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Prognosis, 03 medical and health sciences, Young Adult, Fluorodeoxyglucose F18, MESH : Adolescent, medicine, Humans, Radiology, Nuclear Medicine and imaging, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, Neoplasm Staging, Retrospective Studies, MESH: Adolescent, PET-CT, MESH: Humans, business.industry, MESH : Humans, MESH : Positron-Emission Tomography, MESH: Adult, MESH: Retrospective Studies, MESH : Fluorodeoxyglucose F18, medicine.disease, Survival Analysis, MESH: Male, Lymphoma, Concomitant, MESH : Biopsy, Positron-Emission Tomography, MESH: Lymphoma, Large B-Cell, Diffuse, Bone marrow, MESH : Survival Analysis, business, Nuclear medicine, Tomography, X-Ray Computed, Diffuse large B-cell lymphoma, MESH: Female
Abstract: International audience; UNLABELLED: In newly diagnosed diffuse large B-cell lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow involvement (BMI) can be low because of sampling error if the BMI is focal and not diffuse. Although (18)F-FDG PET/CT is now recommended for initial staging of DLBCL, its role regarding BMI is not well defined. This study evaluated whether (18)F-FDG PET/CT, in comparison with BMB, is useful for the detection of BMI and predictive of outcome. METHODS: From the 142 patients who were referred to our institution for newly diagnosed DLBCL from June 2006 to October 2011, 133 were retrospectively enrolled in our study. All patients underwent whole-body (18)F-FDG PET/CT and a BMB from the iliac crest before any treatment. (18)F-FDG PET/CT was considered positive for BMI in cases of uni- or multifocal bone marrow (18)F-FDG uptake that could not be explained by benign findings on the underlying CT image or history. A final diagnosis of BMI was considered if the BMB was positive or if the positive (18)F-FDG PET/CT was confirmed by guided biopsy or targeted MR imaging or in cases of disappearance of focal bone marrow uptake concomitant with the disappearance of uptake in other lymphoma lesions on (18)F-FDG PET/CT monitoring. Progression-free survival and overall survival were analyzed using the Cox proportional hazards regression model. RESULTS: Thirty-three patients were considered to have BMI. Of these, 8 were positive according to the BMB and 32 were positive according to (18)F-FDG PET/CT. (18)F-FDG PET/CT was more sensitive (94% vs. 24%; P < 0.001), showed a higher negative predictive value (98% vs. 80%), and was more accurate (98% vs. 81%) than BMB. Median follow-up was 24 mo (range, 1-67 mo). Twenty-nine patients (22%) experienced recurrence or disease progression during follow-up, and 20 patients died (15%). In multivariate analysis, only the International Prognostic Index and the (18)F-FDG PET/CT bone marrow status were independent predictors of progression-free survival (P = 0.005 and 0.02, respectively), whereas only the International Prognostic Index remained an independent predictor of overall survival (P = 0.004). CONCLUSION: Assessment of BMI with (18)F-FDG PET/CT provides better diagnostic performance and prognostic stratification in newly diagnosed DLBCL than does BMB.
Published: 2013

56. Varicella-like cutaneous toxoplasmosis in a patient with aplastic anemia

Author: Jessica C. Hassel, Annette Kapaun, Paul Schnitzler, Eva Hadaschik, Daniel Ajzenberg, Alexander H. Dalpke, Nicola Lehners, Klara Tenner-Racz, Stefan Zimmermann, Centre National de Référence (CNR) Toxoplasmose/Toxoplasma Biological Resource Center (BRC) (CNR Toxoplasmose-Toxoplasma BRC), CHU Limoges, Université de Limoges (UNILIM), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), and Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Pathology, Biopsy, Case Reports, Polymerase Chain Reaction, MESH: Biopsy, 0302 clinical medicine, Chickenpox, MESH: Anemia, Aplastic, Skin, 0303 health sciences, MESH: Middle Aged, biology, medicine.diagnostic_test, MESH: Toxoplasma, Anemia, Aplastic, Middle Aged, Immunohistochemistry, 3. Good health, MESH: Chickenpox, MESH: Toxoplasmosis, Female, Toxoplasma, Toxoplasmosis, Microbiology (medical), medicine.medical_specialty, Anemia, 030231 tropical medicine, Diagnosis, Differential, 03 medical and health sciences, MESH: Skin, MESH: Diagnosis, Differential, medicine, Humans, Aplastic anemia, MESH: Humans, 030306 microbiology, business.industry, Toxoplasma gondii, MESH: Immunohistochemistry, MESH: Polymerase Chain Reaction, medicine.disease, biology.organism_classification, Skin biopsy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Differential diagnosis, business, MESH: Female
Abstract: A 60-year-old patient with aplastic anemia presented with vesicular varicella-like skin lesions on her face, arms, legs, back, and abdomen. However, diagnosis for herpetic infection was negative. Findings of a skin biopsy led to a tentative histologic diagnosis of toxoplasmosis, and infection with Toxoplasma gondii was confirmed by immunohistochemistry and PCR. Cutaneous toxoplasmosis is a rare finding in immunocompromised patients and might mimic other infectious diseases, and vesicular lesions associated with toxoplasmosis have not been reported previously.
Published: 2013

57. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience

Author: Pierre Laurent-Puig, Jean-François Emile, Marie-Claude Gorisse, Pascaline Aucouturier, Jean-Philippe Merlio, Florence de Fraipont, Jean-Louis Merlin, Isabelle Durand-Zaleski, Frédérique Nowak, Karen Leroy, Thierry Frebourg, Alain Morel, Hélène Blons, Delphine Le Corre, Gilles Chatellier, Jean-François Côté, Jean-Christophe Sabourin, L'Houcine Ouafik, Etienne Rouleau, Jean-Christophe Boyer, Nathanaël Charrier, Jean-Christophe Pages, Gérard Milano, Patricia de Cremoux, Bases moléculaires de la réponse aux xénobiotiques (U775 (IFR95)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Oncogénétique, CRLCC René Huguenin, Service de Santé Publique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherches Cliniques de Montréal (IRCM), Université de Montréal (UdeM), Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours (UT)-EA3856, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biochimie [CHRU Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Bordeaux [Bordeaux], Oppelia, Institut Jean Godinot [Reims], UNICANCER, Hôpital Saint Louis, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de pharmacogénomique, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA)-UNICANCER-Université Côte d'Azur (UCA), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Centre Alexis Vautrin (CAV), CHU Rouen, Normandie Université (NU), Institut national du cancer [Boulogne] (INCA), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Service d'anatomie pathologique [CHU Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Département de la recherche clinique et du développement, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Unité de Recherche Clinique en Economie de la santé d'Ile de France (URC Eco), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours-EA3856, Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherches Cliniques de Montréal, Université de Montréal, Université de Montréal [Montréal], Biochimie et Physiologie Moléculaire des Plantes (BPMP), Université de Montpellier (UM)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS), Institut Jean Godinot, CRLCC Jean Godinot, CHU Saint Louis [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CRLCC Antoine Lacassagne, Laboratoire épidémiologie et oncogénèse des tumeurs digestives, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service d'anatomie pathologique, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Unité de Recherche Clinique en Economie de la santé d'Ile de France (URC Eco), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), Bases moléculaires de la réponse aux xénobiotiques ( U775 (IFR95) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques de l'Hopital Europeen Georges Pompidou, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Montréal, CHRU Tours, Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Biochimie et Physiologie Moléculaire des Plantes ( BPMP ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ) -Centre international d'études supérieures en sciences agronomiques ( Montpellier SupAgro ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro ) -Institut national de la recherche agronomique [Montpellier] ( INRA Montpellier ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Centre de Recherches en Oncologie biologique et Oncopharmacologie ( CRO2 ), Aix Marseille Université ( AMU ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche en Automatique de Nancy ( CRAN ), Université de Lorraine ( UL ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Alexis Vautrin ( CAV ), Institut national du cancer [Boulogne] ( INCA ), Génétique du cancer et des maladies neuropsychiatriques ( GMFC ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Ambroise Paré, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Unité de Recherche Clinique en Economie de la santé d'Ile de France (URC Eco), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique ( MEPPOT - U1147 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Merlin, Jean-Louis
Subjects: Oncology, Colorectal cancer, Epidemiology, Molecular oncology, MESH: Antibodies, Monoclonal, 0302 clinical medicine, MESH : Fixatives, MESH: Fixatives, Neoplasm Metastasis, lcsh:Science, MESH: Tissue Embedding, 0303 health sciences, MESH: Genetic Testing, Antibodies, Monoclonal, 3. Good health, MESH: Reproducibility of Results, ErbB Receptors, [ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], 030220 oncology & carcinogenesis, MESH : Neoplasm Metastasis, MESH : Proto-Oncogene Proteins, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Medicine, MESH : Colorectal Neoplasms, MESH : Sensitivity and Specificity, MESH: ras Proteins, medicine.medical_specialty, MESH: Receptor, Epidermal Growth Factor, Gastroenterology and Hepatology, Sensitivity and Specificity, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Fixatives, MESH : Genetic Testing, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], External quality assessment, Gastrointestinal Tumors, Cancer Detection and Diagnosis, Humans, Genetic Testing, Genotyping, Biology, MESH: Humans, Tissue Embedding, MESH : Reproducibility of Results, MESH : Humans, lcsh:R, medicine.disease, MESH: Neoplasm Metastasis, MESH: Sensitivity and Specificity, MESH : Biopsy, ras Proteins, lcsh:Q, MESH : Sequence Analysis, DNA, MESH: Sequence Analysis, DNA, Biopsy, Cancer Treatment, lcsh:Medicine, Bioinformatics, medicine.disease_cause, MESH : Tissue Embedding, MESH: Biopsy, MESH : Receptor, Epidermal Growth Factor, Gastrointestinal Cancers, Sanger sequencing, Multidisciplinary, Drug development, MESH : Antibodies, Monoclonal, symbols, KRAS, France, Colorectal Neoplasms, Research Article, MESH: Cell Line, Tumor, Clinical Research Design, Rectal Cancer, symbols.namesake, Antibody Therapy, Diagnostic Medicine, Molecular genetics, Internal medicine, Cell Line, Tumor, Proto-Oncogene Proteins, medicine, MESH : France, 030304 developmental biology, Population Biology, MESH : Cell Line, Tumor, business.industry, Reproducibility of Results, Cancers and Neoplasms, Sequence Analysis, DNA, MESH: France, MESH: Proto-Oncogene Proteins, Gastric Cancer, MESH : ras Proteins, business, MESH: Colorectal Neoplasms
Abstract: International audience; PURPOSE: Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in colorectal cancer, and anti-EGFR antibodies use was limited to KRAS wild type tumors. In order to ensure wide access to tumor molecular profiling, the French National Cancer Institute (INCa) has set up a national network of 28 regional molecular genetics centers. Concurrently, a nationwide external quality assessment for KRAS testing (MOKAECM) was granted to analyze reproducibility and costs. METHODS: 96 cell-line DNAs and 24 DNA samples from paraffin embedded tumor tissues were sent to 40 French laboratories. A total of 5448 KRAS results were collected and analyzed and a micro-costing study was performed on sites for 5 common methods by an independent team of health economists. RESULTS: This work provided a baseline picture of the accuracy and reliability of KRAS analysis in routine testing conditions at a nationwide level. Inter-laboratory Kappa values were >0.8 for KRAS results despite differences detection methods and the use of in-house technologies. Specificity was excellent with only one false positive in 1128 FFPE data, and sensitivity was higher for targeted techniques as compared to Sanger sequencing based methods that were dependent upon local expertise. Estimated reagent costs per patient ranged from €5.5 to €19.0. CONCLUSION: The INCa has set-up a network of public laboratories dedicated to molecular oncology tests. Our results showed almost perfect agreements in KRAS testing at a nationwide level despite different testing methods ensuring a cost-effective equal access to personalized colorectal cancer treatment.
Published: 2013

58. Effect of human skin explants on the neurite growth of the PC12 cell line

Author: Jean-Pierre Pennec, Christelle Le Gall, Nicolas Lebonvallet, Gilles Pauly, Laurent Misery, Ulysse Pereira, Louis Danoux, Jérémy Chéret, Christine Jeanmaire, Nicholas Boulais, Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Laboratoire Mouvement Sport Santé (M2S), École normale supérieure - Cachan (ENS Cachan)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-Université de Brest (UBO)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Laboratoire d'Anatomie Pathologique, Hôpital Morvan Brest-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoires Sérobiologiques, Division of Cognis France now part of BASF, and École normale supérieure - Cachan (ENS Cachan)-Université de Rennes (UR)-Université de Brest (UBO)-Université de Rennes 2 (UR2)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: Pathology, Biopsy, PC12 cell line, Human skin, Cell Communication, PC12 Cells, Biochemistry, chemistry.chemical_compound, MESH: Biopsy, 0302 clinical medicine, Nerve Growth Factor, MESH: Animals, MESH: Nerve Growth Factor, Skin, 0303 health sciences, medicine.diagnostic_test, integumentary system, Cell biology, medicine.anatomical_structure, MESH: Models, Animal, Models, Animal, medicine.medical_specialty, Neurite, MESH: Rats, Dermatology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, MESH: Coculture Techniques, 03 medical and health sciences, MESH: Skin, MESH: Cell Proliferation, MESH: Cell Communication, Neurites, medicine, Animals, Humans, MESH: PC12 Cells, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Molecular Biology, Cell Proliferation, 030304 developmental biology, MESH: Humans, MESH: Neurites, Coculture Techniques, Rats, Nerve growth factor, nervous system, chemistry, Cell culture, Neuron, 030217 neurology & neurosurgery, Explant culture
Abstract: International audience; The skin is a densely innervated organ. After a traumatic injury, such as an amputation, burn or skin graft, nerve growth and the recovery of sensitivity take a long time and are often incomplete. The roles played by growth factors and the process of neuronal growth are crucial. We developed an in vitro model of human skin explants co-cultured with a rat pheochromocytoma cell line differentiated in neuron in presence of nerve growth factor (NGF). This model allowed the study of the influence of skin explants on nerve cells and nerve fibre growth, probably through mediators produced by the explant, in a simplified manner. The neurite length of differentiated PC12 cells co-cultured with skin explants increased after 6 days. These observations demonstrated the influence of trophic factors produced by skin explants on PC12 cells.
Published: 2013

59. MAPPED study design: A 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging

Author: Alex Kirkham, Mathias Winkler, Alex Freeman, Charles Jameson, Caroline M. Moore, Brandon Whitcher, Gareth Ambler, Simon Bott, Anita Mitra, Giulio Gambarota, Nicola L. Robertson, Clare Allen, Mark Emberton, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, Time Factors, Biopsy, MESH: Organ Size, 030232 urology & nephrology, law.invention, MESH: 5-alpha Reductase Inhibitors, MESH: Dose-Response Relationship, Drug, MESH: Magnetic Resonance Imaging, chemistry.chemical_compound, Prostate cancer, MESH: Biopsy, 0302 clinical medicine, 5-alpha Reductase Inhibitors, Randomized controlled trial, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, law, Prostate, Pharmacology (medical), MESH: Double-Blind Method, Prospective Studies, Prospective cohort study, MESH: Treatment Outcome, Randomised controlled trial, medicine.diagnostic_test, General Medicine, Organ Size, MESH: Follow-Up Studies, 3. Good health, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Adult, medicine.medical_specialty, Urology, Placebo, MESH: Prostate, MESH: Azasteroids, 03 medical and health sciences, Magnetic resonance imaging, Double-Blind Method, medicine, Humans, Gynecology, MESH: Humans, Dose-Response Relationship, Drug, business.industry, MESH: Time Factors, Cancer, Prostatic Neoplasms, MESH: Adult, Dutasteride, medicine.disease, MESH: Prospective Studies, MESH: Male, chemistry, Azasteroids, MESH: Prostatic Neoplasms, business, Follow-Up Studies
Abstract: International audience; OBJECTIVE: To evaluate the percentage change in volume of prostate cancer, as assessed by T2-weighted MRI, following exposure to dutasteride (Avodart) 0.5mg daily for six months. PATIENTS AND METHODS: MRI in Primary Prostate cancer after Exposure to Dutasteride (MAPPED) is a double-blind, placebo-controlled trial, supported by GlaxoSmithKline (GSK). Men with prostate cancer suitable for active surveillance (low-intermediate risk prostate cancer on biopsy), and a visible lesion on T2-weighted MRI of at least 0.2 cc, were eligible for consideration. Forty-two men were randomised to 6 months of daily dutasteride 0.5mg or placebo. Multi-parametric MRI (mpMRI) scans were performed at baseline, 3 and 6 months. The percentage changes in cancer volume over time will be compared between the dutasteride and placebo groups. Planned analyses will examine the association between tumour volume and characteristics (perfusion and contrast washout) as seen on mpMRI, HistoScan ultrasound and biopsy histopathology in both groups. DISCUSSION: MAPPED is the first randomised controlled trial to use mpMRI to look at the effect of dutasteride on the volume of prostate cancer. If dutasteride is shown to reduce the volume of prostate cancer, it might be considered as an adjunct for men on active surveillance. Analysis of the placebo arm will allow us to comment on the short-term natural variability of the MR appearance in men who are not receiving any treatment. CONCLUSION: MAPPED will evaluate the short-term effect of dutasteride on prostate cancer volume, as assessed by mpMRI, in men undergoing active surveillance for low or intermediate risk prostate cancer. The study completed recruitment in January 2012.
Published: 2013

60. Facteurs prédictifs de la douleur dans les gestes techniques dermatologiques. [Predictive factors for pain in technical dermatological procedures]

Author: Talour, Karen, Schollhammer, M., Garlantezec, Ronan, Quinio, B., Misery, Laurent, Service de dermatologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de santé publique [Brest], Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan
Subjects: Laser, MESH: Pain Measurement, MESH: Anesthesia, MESH: Curettage, Douleur, Facteurs prédictifs, MESH: Adrenal Cortex Hormones, MESH: Biopsy, MESH: Cryotherapy, Antalgie, MESH: Pain, Postoperative, MESH: Debridement, MESH: Adolescent, MESH: Aged, MESH: Dermatologic Surgical Procedures, MESH: Humans, MESH: Middle Aged, MESH: Hyaluronic Acid, MESH: Questionnaires, MESH: Botulinum Toxins, Type A, MESH: Injections, Intralesional, MESH: Injections, Subcutaneous, MESH: Adult, MESH: Male, MESH: Prospective Studies, MESH: France, MESH: Laser Therapy, MESH: Young Adult, Biopsie, Chirurgie cutanée, MESH: Female, Cryothérapie, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; BACKGROUND: Technical procedures in dermatology are painful. AIM: The aim of the study was to determine predictive factors for pain in such procedures. PATIENTS AND METHODS: This observational study evaluated pain by means of a numerical pain rating scale and a questionnaire about the circumstances of the pain and the use of analgesic methods. Data were analysed using Excel and SAS software. RESULTS: Five hundred and forty-six questionnaires were analysed. Among the patients, 45.4% had mild pain, 34.5% moderate pain and 20.1% severe pain. The least painful procedures were cryotherapy, surgical excision and biopsy, debridement and curettage. Procedures causing moderate to severe pain were treatments involving laser and lights as well as injections (hyaluronic acid, intralesional corticosteroids, botulinum toxin). Pain scores were higher for procedures involving fingers, toes and armpits, while the least painful areas were the trunk and limbs. Among the patients, 62.5% had no preventive analgesia before the procedure, 37.5% had preventive analgesia and 34.2% underwent local or topical anaesthesia (3.7% by cold, 2.0% by oral premedication, 0.5% by hypnosis and 0.4% by nitrous oxide). CONCLUSION: Awareness of predictive factors for pain could allow better use of analgesic methods to offer the patient relief and improve the quality of the procedure.
Published: 2013

61. Atypical hyperplasia of the breast: the black hole of routine breast cancer screening

Author: Picouleau, E., Denis, M., Vincent LAVOUE, Tas, P., Mesbah, H., Poree, P., Leveque, J., Morcel, K., Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], CHU Pontchaillou [Rennes], CRLCC Eugène Marquis (CRLCC), Département de chirurgie, Département d'informatique médicale, Service de Biologie, and Le Corre, Morgane
Subjects: Biopsy, atypical epithelial hyperplasia, MESH: Mammography, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Diagnosis, Differential, MESH: Biopsy, [SDV.CAN] Life Sciences [q-bio]/Cancer, columnar cell metaplasia, MESH: Diagnosis, Differential, Humans, MESH: Early Detection of Cancer, Breast, MESH: Breast, Early Detection of Cancer, Aged, MESH: Aged, Hyperplasia, MESH: Middle Aged, MESH: Humans, MESH: Hyperplasia, screening, Mammogram, Middle Aged, lobular intraepithelial neoplasia, Female, MESH: Female, MESH: Breast Neoplasms, Mammography
Abstract: International audience; AIM: Determination of the prevalence, of the radiological and clinical characteristics, and outcome of atypical hyperplasia (AH) of the breast within a population subjected to routine screening (double-view mammography with double reading, performed every two years between 50 and 75 years of age). PATIENTS AND METHODS: The clinical and radiological records and histological findings of percutaneous and surgical biopsy specimens of sixty-eight patients presenting with AH were reviewed together with patient follow-up data after percutaneous and surgical biopsy. RESULTS: AH incidence in the population was 0.19‰ with the following distribution of lesions: atypical epithelial hyperplasia (AEH, 53%), columnar cell metaplasia with atypia (CCMA, 32%), and lobular intraepithelial neoplasia (LIN, 8%). The mean patient age was 58 years and 24% of patients were receiving hormone replacement therapy. The main radiological finding was the presence of microcalcifications for AEH and CCMA lesions in particular, and the mammograms were valid (correlation between American College of Radiology score and risk of lesion, only 3% of lesions were recognized on the second reading). A total of 13.7% of AH cases were underestimated and a real risk of AH progression was observed, regardless of whether or not surgical biopsy had been performed. CONCLUSION: The clinical and radiological characteristics of AH observed in a population subjected to routine breast cancer screening are identical to those for patients with the same lesions referred to specialist centers. Surgical biopsy remains the recommended option due to the risk of underestimation of lesions by percutaneous biopsy and the risk of progression justifies the need for continued close monitoring.
Published: 2012

62. TGFβ-dependent epithelial-to-mesenchymal transition is required to generate cardiospheres from human adult heart biopsies

Author: Ann Zeuner, Mark Mercola, Alessandro Giacomello, Francesco Angelini, Fabio Miraldi, Isotta Chimenti, Elisa Messina, Elvira Forte, Department of Molecular Medicine, Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Department of Cardiovascular Physiopathology, Anesthesiology and General Surgery, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Department of Biotechnology and Medical - Surgical Sciences, Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita [Rome], Sanford Burnham Medical Research Institute, and La Jolla
Subjects: Cellular differentiation, Biopsy, Myocardial Ischemia, Fluorescent Antibody Technique, MESH: Myocytes, Cardiac, 030204 cardiovascular system & hematology, MESH: Receptor, Notch1, Regenerative medicine, MESH: Benzamides, MESH: Biopsy, 0302 clinical medicine, Transforming Growth Factor beta, Myocytes, Cardiac, MESH: Dioxoles, Receptor, Notch1, MESH: Fluorescent Antibody Technique, Cells, Cultured, 0303 health sciences, Cutting-Edge Communications, Stem Cells, MESH: Regeneration, Cell Differentiation, Hematology, MESH: Transcription Factors, MESH: Gene Expression Regulation, Cell biology, Benzamides, MESH: Myocardial Ischemia, MESH: Receptors, Transforming Growth Factor beta, Stem cell, MESH: Cells, Cultured, Adult, MESH: Cell Differentiation, Epithelial-Mesenchymal Transition, MESH: Myocardium, Dioxoles, MESH: Stem Cells, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, 03 medical and health sciences, MESH: Gene Expression Profiling, Humans, Regeneration, epithelial-to-mesenchymal transition, TGF-beta, cardiac progenitor cells, Epithelial–mesenchymal transition, MESH: Transforming Growth Factor beta, 030304 developmental biology, MESH: Humans, Regeneration (biology), Gene Expression Profiling, Myocardium, MESH: Biological Markers, MESH: Adult, Cell Biology, Transforming growth factor beta, MESH: Epithelial-Mesenchymal Transition, Gene Expression Regulation, Immunology, biology.protein, Snail Family Transcription Factors, Receptors, Transforming Growth Factor beta, Ex vivo, Biomarkers, Developmental Biology, Transforming growth factor, Transcription Factors
Abstract: International audience; Autologous cardiac progenitor cells (CPCs) isolated as cardiospheres (CSps) represent a promising candidate for cardiac regenerative therapy. A better understanding of the origin and mechanisms underlying human CSps formation and maturation is undoubtedly required to enhance their cardiomyogenic potential. Epithelial-to-mesenchymal transition (EMT) is a key morphogenetic process that is implicated in the acquisition of stem cell-like properties in different adult tissues, and it is activated in the epicardium after ischemic injury to the heart. We investigated whether EMT is involved in the formation and differentiation of human CSps, revealing that an up-regulation of the expression of EMT-related genes accompanies CSps formation that is relative to primary explant-derived cells and CSp-derived cells grown in a monolayer. EMT and CSps formation is enhanced in the presence of transforming growth factor β1 (TGFβ1) and drastically blocked by the type I TGFβ-receptor inhibitor SB431452, indicating that TGFβ-dependent EMT is essential for the formation of these niche-like 3D-multicellular clusters. Since TGFβ is activated in the myocardium in response to injury, our data suggest that CSps formation mimics an adaptive mechanism that could potentially be enhanced to increase in vivo or ex vivo regenerative potential of adult CPCs.
Published: 2012

63. Apport clinique de l'Urostation®: mesure du taux de détection de cancer de prostate par biopsies dans le lobe droit et le lobe gauche et comparaison d’une cartographie avec 12 biopsies versus 2 à 3 biopsies dirigées vers une cible IRM

Author: COFFIN, Grégoire, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), and Pierre Mozer
Subjects: MESH: Biopsy, MESH: Selection Bias, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Prostate, Biopsies ciblées, Fusion d’image, MESH: Prostate, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Surface d’échantillonnage, MESH: Magnetic Resonance Imaging, MESH: Neoplasm, Cancer, IRM
Abstract: To distinguish significant from non significant prostate cancer is a current major point for urologists. To achieve this goal, it is essential to improve the methodology of prostate biopsy procedure because they still are the only way to confirm the presence of cancer inside the prostate. The Urostation® system, which includes a 3D ultrasound probe and an original image fusion software, allowed us to find some interesting results among a homogenous population of patients who were at risk of localized prostate cancer: the way we are doing prostate biopsies was not symmetrical between the right and the left prostate lobe. 2 or 3 MRI targeted cores among a population of patients who presented abnormal multiparametric MRI results could be sufficient for cancer staging and could prevent the use of 12 usual systematic prostate cores.; La nécessité de différencier un cancer de prostate cliniquement significatif et d’un cancer indolent est devenue un objectif clinique majeur. Cela suppose une amélioration des méthodes de biopsies de prostate qui sont le seul moyen de réaliser le diagnostic de cancer et restent un facteur pronostique important. L’Urostation®, qui associe un échographe 3D avec un logiciel de fusion d’image, a permis de mettre en évidence sur une population homogène de patients à risque de cancer localisé : d’une part que les biopsies n’étaient pas réalisées de façon symétrique entre le lobe droit et le lobe gauche d’autre part que la réalisation de biopsies ciblées dans une population de patients présentant une IRM multiparamétrique anormale pourrait permettre de ne plus avoir recours à un schéma de 12 biopsies systématiques mais uniquement à 2 ou 3 biopsies ciblées.
Published: 2012

64. Pseudotumoral cutaneous aspergillosis in chronic granulomatous disease, report of a pediatric case

Author: Aida Borgi, Monia Kharfi, Samir Boubaker, Sihem Barsaoui, Monia Khemiri, Nadia El Fekih, and Université de Tunis El Manar (UTM)
Subjects: Antifungal Agents, Biopsy, [SDV]Life Sciences [q-bio], chronic granulomatous disease, Aspergillosis, Granulomatous Disease, Chronic, MESH: Biopsy, 0302 clinical medicine, Chronic granulomatous disease, MESH: Granulomatous Disease, Chronic, 030212 general & internal medicine, MESH: Treatment Outcome, MESH: Dermatomycoses, Invasive Pulmonary Aspergillosis, 0303 health sciences, child, medicine.diagnostic_test, Cutaneous aspergillosis, Osteomyelitis, General Medicine, 3. Good health, Treatment Outcome, Child, Preschool, Drainage, Female, medicine.medical_specialty, skin, MESH: Invasive Pulmonary Aspergillosis, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, MESH: Osteomyelitis, Pathology and Forensic Medicine, MESH: Drainage, 03 medical and health sciences, MESH: Skin, medicine, Dermatomycoses, Humans, Surgical Wound Infection, In patient, MESH: Surgical Wound Infection, MESH: Debridement, invasive aspergillosis, MESH: Humans, 030306 microbiology, business.industry, MESH: Child, Preschool, Invasive pulmonary aspergillosis, medicine.disease, MESH: Antifungal Agents, Debridement, Etiology, business, MESH: Female, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; Invasive aspergillosis is a life-threatening condition in patients with chronic granulomatous disease (CGD). Skin invasion by Aspergillus occurs most commonly by contiguity to a neighboring cavity. We describe an unusual case of invasive cutaneous aspergillosis presented as a large burgeoning tumor in a 4-year-old girl with CGD who underwent surgical treatment for bifocal osteomyelitis of the left leg. The skin invasion occurred 4 months after a "successful" treatment of invasive pulmonary aspergillosis. Atypical presentation and diagnostic difficulties are discussed. Invasive cutaneous aspergillosis may be polymorphic. The diagnosis should be considered early in the etiological investigation of any suspicious skin lesions in CGD even in uncommon aspects such as burgeoning tumors.
Published: 2012

65. [Accuracy of prostate biopsies to evaluate tumor location in prostate cancer]

Author: J, Lillaz, G, Delorme, G, Guichard, S, Bernardini, E, Chabannes, H, Bittard, F, Kleinclauss, Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Saas, Philippe, Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
Subjects: Male, Prostatectomy, MESH: Aged, MESH: Humans, MESH: Middle Aged, [SDV.IMM] Life Sciences [q-bio]/Immunology, Biopsy, Prostate, Prostatic Neoplasms, Reproducibility of Results, MESH: Retrospective Studies, Middle Aged, urologic and male genital diseases, MESH: Prostate, MESH: Male, MESH: Reproducibility of Results, MESH: Biopsy, MESH: Prostatectomy, MESH: Prostatic Neoplasms, Humans, [SDV.IMM]Life Sciences [q-bio]/Immunology, Aged, Retrospective Studies
Abstract: International audience; INTRODUCTION: The therapeutic approach of prostate cancer depends mainly on pathological criteria obtained through prostate biopsy. The low accuracy of prostate biopsy for Gleason grade determination is well known but its accuracy for bilateral or multifocal tumor has not been evaluated. The goal of this study was to assess the concordance between prostate biopsy and whole prostate specimen obtained after radical prostatectomy especially for bilateral and/or multifocal tumor. METHODS: We retrospectively compared the pathological results of prostate biopsy cores to the prostate specimen in patients who underwent radical prostatectomy in our department between the 01/01/1999 and the 31/12/2008. The criteria analyzed were the Gleason score, tumor bilaterality or multifocality. The impact of the number of prostate biopsy cores was also analyzed. RESULTS: Two hundred and five complete histological records were studied. Regarding the Gleason score overall concordance was 55%. In 38%, prostate biopsies downgraded the Gleason score. This concordance decreased with tumor differentiation (90.6% for Gleason 6 vs. 31% for Gleason greater than 7). For the tumor bilaterality, 78% of cancers affected both lobes at the definitive specimen analysis while only 49% were bilateral at prostate biopsies, achieving a concordance of 61%. Multifocal disease was observed in 36% at definitive pathology analysis with low concordance with prostate biopsies (36%). The number of biopsies increased the concordance for the Gleason score (60 to 81% for Gleason 7 and from 28 to 50% for Gleason greater than 7) and tumor location (44 to 70%). CONCLUSION: Pathological criteria and tumor mapping obtained from prostate biopsies were not very reliable especially when the tumor was poorly differentiated. An increased number of prostate biopsy core improved the sensitivity and specificity for the Gleason score diagnostic and of the tumor mapping.
Published: 2012

66. [Kidney and HIV infection]

Author: Plaisier, Emmanuelle, Lescure, François-Xavier, Ronco, Pierre, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service des maladies infectieuses et tropicales [CHU Tenon], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), RONCO, Pierre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
Subjects: MESH: Kidney Diseases, MESH: Adenine, MESH: Humans, urogenital system, MESH: Virus Replication, MESH: Genetic Predisposition to Disease, virus diseases, MESH: Kidney, MESH: Receptor, Epidermal Growth Factor, urologic and male genital diseases, female genital diseases and pregnancy complications, MESH: Male, MESH: HIV-1, MESH: Biopsy, MESH: Glomerular Filtration Rate, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], MESH: African Continental Ancestry Group, MESH: Anti-HIV Agents, MESH: Phosphorus, MESH: AIDS-Associated Nephropathy, MESH: Organophosphonates, MESH: Female
Abstract: International audience; Screening of chronic kidney disease (CKD) that includes estimation of the glomerular filtration rate (GFR) and evaluation proteinuria should be performed in all HIV-infected patients and these parameters have to be monitored annually in patients at higher risk for CKD. Black patients have a genetic predisposition to develop HIV-associated nephropathy. Suppression of HIV viral replication with antiretroviral therapy prevents the development of HIV-associated nephropathy or halts its progression. Kidney biopsy remains the most informative diagnosis test to differentiate various forms of kidney diseases in HIV-infected patients. Dosing antiretroviral agents with kidney metabolism should be adjusted when eGFR is bellow 50 mL/min/1.73 m(2). eGFR and serum phosphorus at baseline and during treatment should be carefully assessed in patients receiving tenofovir. Proximal renal tubular toxicity must be further evaluated in the presence of eGFR decrease and/or hypophosphatemia under tenofovir therapy.
Published: 2012

67. Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry

Author: P, Calès, J P, Zarski, J Marc, Chapplain, S, Bertrais, N, Sturm, C, Michelet, G, Babany, J, Chaigneau, M, Eddine Charaf, Dominique, Guyader, SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), Epidémiologie pronostique des cancers et affections graves, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Fibrosys, ANRS HC 12, and Fibrostop
Subjects: Adult, Male, MESH: Antiviral Agents, MESH: Clinical Trials as Topic, Biopsy, Antiviral Agents, Sensitivity and Specificity, MESH: Pathology, Clinical, MESH: Hematologic Tests, MESH: Biopsy, Humans, MESH: Interferons, liver biopsy, Aged, liver fibrosis, MESH: Aged, Clinical Trials as Topic, Hematologic Tests, Pathology, Clinical, MESH: Middle Aged, MESH: Humans, noninvasive tests, Reproducibility of Results, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, interferon, Hepatitis C, Chronic, Middle Aged, Fibrosis, MESH: Male, MESH: Sensitivity and Specificity, MESH: Hepatitis C, Chronic, MESH: Reproducibility of Results, Liver, MESH: Fibrosis, Female, Interferons, hepatitis C, MESH: Female, morphometry, MESH: Liver
Abstract: International audience; We evaluated whether quantitative measurements of liver fibrosis with recently developed diagnostics outperform histological staging in detecting natural or interferon-induced changes. We compared Metavir staging, morphometry (area and fractal dimension) and six blood tests in 157 patients with chronic hepatitis C from two trials testing maintenance interferon for 96 weeks. Paired liver biopsies and blood tests were available for 101 patients, and there was a significant improvement in Metavir activity and a significant increase in blood tests reflecting fibrosis quantity in patients treated with interferon when compared with controls - all per cent changes in histological fibrosis measures were significantly increased in F1 vs F2-4 stages only in the interferon group. For the whole population studied between weeks 0 and 96, there was significant progression only in the area of fibrosis (AOF) (P = 0.026), FibroMeter (P = 0.020) and CirrhoMeter (P = 0.003). With regards to dynamic reproducibility, agreement was good (r(ic) ≥ 0.72) only for Metavir fibrosis score, FibroMeter and CirrhoMeter. The per cent change in AOF was significantly higher than that of fractal dimension (P = 0.003) or Metavir fibrosis score (P = 0.015). CirrhoMeter was the only blood test with a change significantly higher than that of AOF (P = 0.039). AOF and two blood tests, reflecting fibrosis quantity, have high sensitivity and/or reproducibility permitting the detection of a small progression in liver fibrosis over two years. A blood test reflecting fibrosis quantity is more sensitive and reproducible than morphometry. The study also shows that maintenance interferon does not improve fibrosis, whatever its stage.
Published: 2012

68. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas

Author: Anne-Valérie Decouvelaere, Emmanuel Watkin, Isabelle Ray-Coquard, Perrine Marec-Berard, Irène Asmane, Dominique Ranchère, Jean-Yves Blay, Laurent Alberti, Jean-Emmanuel Kurtz, Jean-Pierre Bergerat, Philippe A. Cassier, Adeline Duc, Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe 11, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Centre Léon Bérard [Lyon], Service d'Oncologie Médicale, Equipe 1, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service d'Oncologie Médicale, Département d'anatomopathologie, biopathologie, Service d'Anatomopathologie, and Altération génétique des cancers, chimioprévention et réponse thérapeutique
Subjects: Male, Cancer Research, Pathology, Time Factors, MESH: Osteosarcoma, Receptor, ErbB-2, medicine.medical_treatment, Biopsy, Kaplan-Meier Estimate, MESH: Antibodies, Monoclonal, Receptor, IGF Type 1, MESH: Biopsy, Insulin-like growth factor, MESH: Receptor, IGF Type 1, 0302 clinical medicine, MESH: Child, Epidermal growth factor receptor, Child, MESH: Treatment Outcome, MESH: Aged, 0303 health sciences, Osteosarcoma, MESH: Middle Aged, Antibodies, Monoclonal, MESH: Insulin-Like Growth Factor Binding Protein 3, Sarcoma, Middle Aged, MESH: Bone Neoplasms, Immunohistochemistry, MESH: Predictive Value of Tests, MESH: Sarcoma, Ewing, 3. Good health, ErbB Receptors, Treatment Outcome, Oncology, MESH: Receptor, erbB-2, MESH: Young Adult, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, France, MESH: Ki-67 Antigen, MESH: Cell Nucleus, Adult, medicine.medical_specialty, MESH: Cell Line, Tumor, Adolescent, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Bone Neoplasms, MESH: Receptor, Epidermal Growth Factor, Sarcoma, Ewing, Biology, Disease-Free Survival, 03 medical and health sciences, Young Adult, Predictive Value of Tests, Cell Line, Tumor, medicine, Biomarkers, Tumor, Humans, MESH: Patient Selection, Progression-free survival, MESH: Kaplan-Meier Estimate, 030304 developmental biology, Aged, MESH: Adolescent, Cell Nucleus, MESH: Humans, Growth factor, Patient Selection, MESH: Time Factors, MESH: Adult, MESH: Immunohistochemistry, medicine.disease, MESH: Male, MESH: France, Insulin-Like Growth Factor Binding Protein 3, Ki-67 Antigen, MESH: Disease-Free Survival, MESH: Sarcoma, MESH: Tumor Markers, Biological, Cancer research, biology.protein, MESH: Antineoplastic Agents, MESH: Female, Immunostaining
Abstract: International audience; AIMS: A minority of patients with advanced sarcoma achieve prolonged progression free survival (PFS) with insulin growth factor type 1 receptor (IGF-1R) monoclonal antibody (Ab) therapy. A biomarker identifying those patients beforehand would be useful to select patients for the development of these agents. METHODS: This single centre series includes patients with unresectable or metastatic soft tissue sarcomas (STS), Ewing sarcoma (ES) and osteosarcoma treated with IGF-1R Ab (R1507, IMC-A12, SCH 717454 and CP-751.871) in the Centre Léon Bérard. Tumour samples were analysed by immunohistochemistry for expression of IGF-1R, insulin-like growth factor binding protein type 3 (IGFBP-3), Ki67, epidermal growth factor receptor (HER1) and human epidermal growth factor receptor 2 (HER2). Predictive factors for PFS and overall survival (OS) were investigated. RESULTS: All tumour samples had a positive IGF-1R immunostaining on 60% to 100% of tumour cells. IGFBP-3 immunostaining was observed in 12 (75%) samples with 5% to 100% of positive cells. IGF-1R immunostaining was nuclear (n=9, 56%), cytoplasmic (n=4, 25%), or nuclear +cytoplasmic (n=3, 19%). Neither IGFBP-3 expression, nor Ki67 was correlated to PFS. HER2 and HER1 staining were positive in 0 and 2 samples respectively (both primary resistant to IGF-1R Ab therapy). Exclusive intra-nuclear immunoreactivity for IGF-1R was significantly associated with a better PFS (p=0.01) and OS (p=0.007). CONCLUSION: Exclusive nuclear localisation of IGF-1R is an easily testable biomarker associated with a better PFS and OS for patients treated with IGF-1R Ab therapy. Nuclear localisation of IGF-1R in tumour cells might be a hallmark of pathway activation.
Published: 2012

69. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive

Author: Isabelle Fouchard-Hubert, Anrs, Jérôme Boursier, Frédéric Oberti, Vindiag multicentric groups from Sniff, Paul Calès, Victor de Ledinghen, Jean-Pierre Zarski, Yves Gallois, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Département d'hépato-gastroentérologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Fibrose hépatique et cancer du foie, Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble-Université Grenoble Alpes (UGA), and Laboratoire de Biochimie
Subjects: Liver Cirrhosis, Male, MESH: Decision Trees, Cirrhosis, Biopsy, MESH: Diagnostic Techniques, Digestive System, MESH: Elasticity Imaging Techniques, MESH: Biopsy, 0302 clinical medicine, Fibrosis, MESH: Middle Aged, medicine.diagnostic_test, Gastroenterology, Hepatitis C, Middle Aged, 3. Good health, MESH: Hepatitis C, Chronic, MESH: Reproducibility of Results, 030220 oncology & carcinogenesis, Liver biopsy, Elasticity Imaging Techniques, Female, 030211 gastroenterology & hepatology, MESH: Liver Cirrhosis, Algorithm, Algorithms, Adult, medicine.medical_specialty, MESH: Algorithms, Sensitivity and Specificity, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH: Humans, Hepatology, business.industry, FibroTest, Decision Trees, MESH: Biological Markers, Reproducibility of Results, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Gastroenterology, Hepatitis C, Chronic, medicine.disease, MESH: Male, MESH: Sensitivity and Specificity, Diagnostic Techniques, Digestive System, business, Hepatic fibrosis, MESH: Female, Biomarkers
Abstract: International audience; UNLABELLED: The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. CONCLUSION: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis.
Published: 2012

70. Delayed noninvasive reduction of large bullae following thoracic irradiation

Author: Noël-Savina, Elise, Leroyer, Christophe, Descourt, Renaud, Alavi, Zarrin, Service d'Oncologie Thoracique (BREST - ICH), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Centre d'Investigation Clinique (CIC - Brest), and Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, MESH: Combined Modality Therapy, Lung Neoplasms, Biopsy, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Treatment of lung cancer, 030218 nuclear medicine & medical imaging, MESH: Biopsy, Blister, 0302 clinical medicine, Medicine, MESH: Radiotherapy Dosage, MESH: Aged, Radiotherapy Dosage, MESH: Carcinoma, Squamous Cell, respiratory system, Combined Modality Therapy, MESH: Positron-Emission Tomography, 3. Good health, medicine.anatomical_structure, Pulmonary Emphysema, MESH: Pulmonary Emphysema, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Radiology, MESH: Tomography, X-Ray Computed, medicine.medical_specialty, MESH: Radiation Injuries, Diagnosis, Differential, MESH: Blister, 03 medical and health sciences, MESH: Diagnosis, Differential, Thoracic Oncology, Humans, Radiology, Nuclear Medicine and imaging, Esophagus, Radiation Injuries, Lung cancer, Aged, Pneumonitis, MESH: Humans, business.industry, Induction chemotherapy, medicine.disease, MESH: Male, Surgery, respiratory tract diseases, MESH: Lung Neoplasms, Radiation therapy, Positron-Emission Tomography, Concomitant, Tomography, X-Ray Computed, business
Abstract: International audience; Chest radiotherapy is a mainstay of management of thoracic oncology patients. Radiotherapy also injures nontarget tissues such as the lungs, coronary arteries, and esophagus, and safe limits to the doses that can be delivered to tumors have been determined empirically. Patients afflicted with lung cancer due to smoking often have concomitant chronic obstructive pulmonary disease which, on occasion, manifests as bullous emphysema. We describe a case and course of treatment of lung cancer found incidentally in a patient followed for severe pulmonary emphysema. Treatment consisted of radiochemotherapy after induction chemotherapy. Three years after the end of antineoplastic treatment, a follow-up computed tomography scan revealed complete retraction of a large emphysematous bulla that had been present prior to treatment.
Published: 2012

71. Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange

Author: Samson , Maxime, Audia , Sylvain, Leguy , Vanessa, Berthier , Sabine, Janikashvili , Nona, Martin , Laurent, Bonnotte , Bernard, Lorcerie , Bernard, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Service de Médecine Interne (SOC 1 et SOC 2) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire de pathologie et cytologie, Saas, Philippe, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
Subjects: MESH: Combined Modality Therapy, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Acute Kidney Injury, MESH: Hydroxychloroquine, MESH : Lupus Nephritis, MESH : Hemolytic-Uremic Syndrome, MESH : Models, Immunological, MESH: Models, Immunological, MESH: Biopsy, MESH : Mycophenolic Acid, MESH : Erythrocytes, Abnormal, immune system diseases, hemic and lymphatic diseases, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, skin and connective tissue diseases, MESH : Immunosuppressive Agents, MESH : Plasma Exchange, MESH : Cyclophosphamide, MESH: Mycophenolic Acid, MESH: Erythrocytes, Abnormal, MESH: Humans, MESH: Methylprednisolone, MESH : Drug Therapy, Combination, MESH : Humans, MESH : Hydroxychloroquine, MESH: Cyclophosphamide, MESH : Prednisone, MESH: Adult, MESH: Kidney, MESH: Plasma Exchange, MESH : Adult, MESH: Lupus Nephritis, MESH : Kidney, MESH: Drug Therapy, Combination, MESH: Hemolytic-Uremic Syndrome, MESH : Biopsy, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH : Methylprednisolone, MESH: Immunosuppressive Agents, MESH : Combined Modality Therapy, MESH: Prednisone, MESH: Female, MESH : Acute Kidney Injury
Abstract: International audience; Systemic lupus erythematosus (SLE) has been described as a cause of thrombotic microangiopathy, especially thrombotic thrombocytopenic purpura (TTP). Haemolytic-uraemic syndrome (HUS) is less frequent in SLE. We report a case of such an association during an episode of severe lupus nephritis in a young woman, who was successfully treated with steroids, cyclophosphamide and especially plasma exchange with plasma replacement. This report highlights the importance of recognising atypical HUS in SLE patients by looking for schistocytes in case of haemolytic anemia with a negative antiglobulin test, in order to begin plasma exchange.
Published: 2012

72. Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis.: HCV variability and steatosis

Author: Depla, Marion, D'Alteroche, Louis, Le Gouge, Amélie, Alain, Moreau, Hourioux, Christophe, Meunier, Jean-Christophe, Gaillard, Julien, De Muret, Anne, Bacq, Yannick, Kazemi, Farhad, Avargues, Aurélie, Roch, Emmanuelle, Piver, Eric, Gaudy-Graffin, Catherine, Giraudeau, Bruno, Roingeard, Philippe, Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours-EA3856, Service de gastro-entérologie [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CIC - Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Biologie Cellulaire, Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), PPF Analyse des Systèmes Biologiques (ASB), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Plate-Forme des Microscopies, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hépatogastroentérologie, Centre Hospitalier de Blois (CHB), Service de Bactériologie-Virologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, This work was supported by grants from INSERM-DHOS 'Recherche Translationnelle: Virostéatose' and by the 'Ligue Contre le Cancer' (Loir et Cher and Ile et Vilaine). M.D. was supported by a fellowship from INSERM-Région Centre and the 'Fondation pour la Recherche Médicale'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., and Université de Tours (UT)-EA3856
Subjects: MESH: Viral Core Proteins, viruses, lipid droplet, MESH: Amino Acid Sequence, liver, MESH: Genotype, MESH: Biopsy, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, steatosis, MESH: Hepacivirus, MESH: Genetic Variation, MESH: Phylogeny, MESH: Fatty Liver, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Molecular Sequence Data, MESH: Conserved Sequence, electron microscopy, MESH: Host-Pathogen Interactions, MESH: Adult, MESH: Male, MESH: Hepatitis C, Chronic, HCV, MESH: Viral Nonstructural Proteins, MESH: Female, MESH: Liver
Abstract: International audience; Most clinical studies suggest that the prevalence and severity of liver steatosis are higher in patients infected with hepatitis C virus (HCV) genotype 3 than in patients infected with other genotypes. This may reflect the diversity and specific intrinsic properties of genotype 3 virus proteins. We analyzed the possible association of particular residues of the HCV core and NS5A proteins known to dysregulate lipid metabolism with steatosis severity in the livers of patients chronically infected with HCV. We used transmission electron microscopy to quantify liver steatosis precisely in a group of 27 patients, 12 of whom were infected with a genotype 3 virus, the other 15 being infected with viruses of other genotypes. We determined the area covered by lipid droplets in liver tissues and analyzed the diversity of the core and NS5A regions encoded by the viral variants circulating in these patients. The area covered by lipid droplets did not differ significantly between patients infected with genotype 3 viruses and those infected with other genotypes. The core and NS5A protein sequences of the viral variants circulating in patients with mild or severe steatosis were evenly distributed throughout the phylogenic trees established from all the collected sequences. Thus, individual host factors seem to play a much greater role than viral factors in the development of severe steatosis in patients chronically infected with HCV, including those infected with genotype 3 viruses.
Published: 2012

73. USF-1 is critical for maintaining genome integrity in response to UV-induced DNA photolesions

Author: Yorann Baron, Marie-Dominique Galibert, Sébastien Corre, Nicolas Mouchet, Sophie Vaulont, Sharon Prince, RTO - Régulation transcriptionnelle et oncogenèse, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Proclaim, Proclaim-Proclaim, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Human Biology, University of Cape Town, Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Service de génétique clinique [Rennes], Université de Rennes (UR)-CHU Pontchaillou [Rennes]-hôpital Sud-CHU Pontchaillou [Rennes]-hôpital Sud, This work was supported by the Ligue National contre le Cancer-Comités Départementaux du Grand Ouest and the Association pour la Recherche contre le Cancer (ARC) foundations. YB has been successively supported by the Conseil Général Région Bretagne (ARED) and the ARC PhD fellowship programs. SC was supported by the CHU-research program and by CNRS., Institut de Génétique et Développement de Rennes ( IGDR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140-Centre National de la Recherche Scientifique ( CNRS ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140-Centre National de la Recherche Scientifique ( CNRS ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140-Centre National de la Recherche Scientifique ( CNRS ) -Proclaim, Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140-Centre National de la Recherche Scientifique ( CNRS ) -Service de génétique clinique [Rennes], Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CHU Pontchaillou [Rennes]-Hôpital Sud-CHU Pontchaillou [Rennes]-Hôpital Sud, De Villemeur, Hervé, Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Proclaim, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Service de génétique clinique [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes]-hôpital Sud-CHU Pontchaillou [Rennes]-hôpital Sud, Faculty of Health Sciences, and Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: DNA Repair, MESH : DNA, MESH : RNA, Small Interfering, Mice, 0302 clinical medicine, Small interfering RNAs, MESH: Animals, MESH: HSP70 Heat-Shock Proteins, Regulation of gene expression, MESH: DNA Repair, 0303 health sciences, MESH : Cell Survival, MESH : Gene Expression Regulation, MESH: Genomic Instability, MESH: Mitochondrial Proteins, Cell biology, MESH: DNA Repair Enzymes, MESH: Cell Survival, 030220 oncology & carcinogenesis, Medicine, MESH : DNA-Binding Proteins, MESH : Carrier Proteins, DNA damage, MESH: Carrier Proteins, Genomic Instability, 03 medical and health sciences, Transcription factors, Genetics, Humans, Biology, Molecular Biology, Ecology, Evolution, Behavior and Systematics, MESH : Mitochondrial Proteins, MESH: DNA Damage, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, MESH : Humans, MESH : HSP70 Heat-Shock Proteins, DNA, DNA Repair Enzymes, chemistry, MESH : Biopsy, Gene expression, Carrier Proteins, [ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatology, [ SDV.GEN ] Life Sciences [q-bio]/Genetics, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Keratinocytes, Genome instability, Cancer Research, Biopsy, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: Mice, Knockout, chemistry.chemical_compound, MESH: Biopsy, MESH : DNA Repair, Molecular Cell Biology, MESH: RNA, Small Interfering, RNA, Small Interfering, MESH : DNA Damage, Genetics (clinical), Mice, Knockout, MESH : Keratinocytes, MESH: DNA, MESH: Upstream Stimulatory Factors, MESH: Gene Expression Regulation, MESH: Keratinocytes, DNA-Binding Proteins, MESH : DNA Repair Enzymes, Research Article, lcsh:QH426-470, Cell Survival, Ultraviolet Rays, DNA repair, Dermatology, Mitochondrial Proteins, MESH : Mice, Immunoprecipitation, Animals, HSP70 Heat-Shock Proteins, Gene, Transcription factor, MESH: Mice, 030304 developmental biology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, MESH : Upstream Stimulatory Factors, Gene regulation, lcsh:Genetics, Gene Expression Regulation, MESH : Ultraviolet Rays, Upstream Stimulatory Factors, MESH : Mice, Knockout, MESH: Ultraviolet Rays, MESH : Animals, MESH : Genomic Instability, MESH: DNA-Binding Proteins, DNA Damage, Nucleotide excision repair
Abstract: An important function of all organisms is to ensure that their genetic material remains intact and unaltered through generations. This is an extremely challenging task since the cell's DNA is constantly under assault by endogenous and environmental agents. To protect against this, cells have evolved effective mechanisms to recognize DNA damage, signal its presence, and mediate its repair. While these responses are expected to be highly regulated because they are critical to avoid human diseases, very little is known about the regulation of the expression of genes involved in mediating their effects. The Nucleotide Excision Repair (NER) is the major DNA–repair process involved in the recognition and removal of UV-mediated DNA damage. Here we use a combination of in vitro and in vivo assays with an intermittent UV-irradiation protocol to investigate the regulation of key players in the DNA–damage recognition step of NER sub-pathways (TCR and GGR). We show an up-regulation in gene expression of CSA and HR23A, which are involved in TCR and GGR, respectively. Importantly, we show that this occurs through a p53 independent mechanism and that it is coordinated by the stress-responsive transcription factor USF-1. Furthermore, using a mouse model we show that the loss of USF-1 compromises DNA repair, which suggests that USF-1 plays an important role in maintaining genomic stability., Author Summary UV is responsible for DNA damage and genetic alterations of key players of the Nucleotide Excision Repair (NER) machinery promote the development of UV-induced skin cancers. The NER is the major DNA–repair process involved in the recognition and removal of UV-mediated DNA damage. Different factors participating in this DNA repair are essential, and their mutations are associated with severe genetic diseases such as Cockayne Syndrome and Xeroderma Pigmentosum. Here, we show for the first time that the specific regulation of expression in response to UV of two NER factors CSA and HR23A is required to efficiently remove DNA lesions and to maintain genomic stability. We also implicate the USF-1 transcription factor in the regulation of the expression of these factors using in vitro and in vivo models. This finding is particularly important because UV is the major cause of skin cancers and dramatically compromises patients with highly sensitive genetic diseases.
Published: 2012

74. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study

Author: Jean-Pierre Bronowicki, Elie-Serge Zafrani, Armelle Poujol-Robert, François Bailly, Dominique Larrey, Marc Bourlière, Albert Tran, Marie-Christine Gelineau, Jérôme Guéchot, Hélène Voitot, Victor de Ledinghen, I. Hubert, Michel Vaubourdolle, Adeline Paris, Dominique Guyader, Nathalie Sturm, Jean-Charles Renversez, Jean-Luc Bosson, Jean-Pierre Zarski, Candice Trocme, Maria Alessandra Rosenthal-Allieri, Tarik Asselah, Renée-Claude Boisson, Frédéric Ziegler, Elisabeth Lasnier, Département d'hépato-gastroentérologie, CHU Grenoble-Université Grenoble Alpes (UGA), Institut Albert Bonniot - Ontogénèse et oncogénèse moléculaires, CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC - Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microenvironnement et remodelage, Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes]-CHU Pontchaillou [Rennes], Département de biologie intégrée, CHU Grenoble-Hôpital Michallon, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Service d'Hépato-Gastroentérologie, Hôpital St Joseph, Service de Biochimie et Génétique Moléculaire, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire d'Immunologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Hôpital Hôtel Dieu, French Clinical Biology Society (Société Francaise de Biologie Clinique), Association for Liver Research (l'Association pour l'Etude du Foie), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], Université Nice Sophia Antipolis (... - 2019) (UNS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Service d'hépato- gastro-entérologie, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes]-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Liver Cirrhosis, Male, Cirrhosis, Transient elastography, Biopsy, MESH: Elasticity Imaging Techniques, Chronic hepatitis C, Gastroenterology, MESH: Biopsy, 0302 clinical medicine, Prospective Studies, Prospective cohort study, 0303 health sciences, Hematologic Tests, MESH: Middle Aged, medicine.diagnostic_test, Hepatitis C, Middle Aged, MESH: Predictive Value of Tests, 3. Good health, MESH: Hepatitis C, Chronic, Liver biopsy, Predictive value of tests, Elasticity Imaging Techniques, 030211 gastroenterology & hepatology, Female, MESH: Liver Cirrhosis, Adult, medicine.medical_specialty, Liver fibrosis, MESH: Hematologic Tests, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, medicine, Humans, 030304 developmental biology, Surrogate markers, Blood tests, MESH: Humans, Hepatology, Receiver operating characteristic, business.industry, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hepatitis C, Chronic, medicine.disease, MESH: Prospective Studies, MESH: Male, Surgery, business, MESH: Female
Abstract: International audience; BACKGROUND & AIMS: Blood tests and transient elastography (Fibroscan™) have been developed as alternatives to liver biopsy. This ANRS HCEP-23 study compared the diagnostic accuracy of nine blood tests and transient elastography (Fibroscan™) to assess liver fibrosis, vs. liver biopsy, in untreated patients with chronic hepatitis C (CHC). METHODS: This was a multicentre prospective independent study in 19 French University hospitals of consecutive adult patients having simultaneous liver biopsy, biochemical blood tests (performed in a centralized laboratory) and Fibroscan™. Two experienced pathologists independently reviewed the liver biopsies (mean length=25±8.4 mm). Performance was assessed using ROC curves corrected by Obuchowski's method. RESULTS: Fibroscan™ was not interpretable in 113 (22%) patients. In the 382 patients having both blood tests and interpretable Fibroscan™, Fibroscan™ performed similarly to the best blood tests for the diagnosis of significant fibrosis and cirrhosis. Obuchowski's measure showed Fibrometer® (0.86), Fibrotest® (0.84), Hepascore® (0.84), and interpretable Fibroscan™ (0.84) to be the most accurate tests. The combination of Fibrotest®, Fibrometer®, or Hepascore® with Fibroscan™ or Apri increases the percentage of well classified patients from 70-73% to 80-83% for significant fibrosis, but for cirrhosis a combination offers no improvement. For the 436 patients having all the blood tests, AUROC's ranged from 0.82 (Fibrometer®) to 0.75 (Hyaluronate) for significant fibrosis, and from 0.89 (Fibrometer® and Hepascore®) to 0.83 (FIB-4) for cirrhosis. CONCLUSIONS: Contrarily to blood tests, performance of Fibroscan™ was reduced due to uninterpretable results. Fibrotest®, interpretable Fibroscan™, Fibrometer®, and Hepascore® perform best and similarly for diagnosis of significant fibrosis and cirrhosis.
Published: 2012

75. Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis.: HCV variability and steatosis

Author: Depla, Marion, d'Alteroche, Louis, Le Gouge, Amélie, Alain, Moreau, Hourioux, Christophe, Meunier, Jean-Christophe, Gaillard, Julien, de Muret, Anne, Bacq, Yannick, Kazemi, Farhad, Avargues, Aurélie, Roch, Emmanuelle, Piver, Eric, Gaudy-Graffin, Catherine, Giraudeau, Bruno, Roingeard, Philippe, Roingeard, Philippe, Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours (UT)-EA3856, Service de gastro-entérologie [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CIC - Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Biologie Cellulaire, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, PPF Analyse des Systèmes Biologiques (ASB), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Plate-Forme des Microscopies, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hépatogastroentérologie, Centre Hospitalier de Blois (CHB), Service de Bactériologie-Virologie, and This work was supported by grants from INSERM-DHOS 'Recherche Translationnelle: Virostéatose' and by the 'Ligue Contre le Cancer' (Loir et Cher and Ile et Vilaine). M.D. was supported by a fellowship from INSERM-Région Centre and the 'Fondation pour la Recherche Médicale'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Subjects: MESH: Viral Core Proteins, viruses, lipid droplet, MESH: Amino Acid Sequence, liver, MESH: Genotype, MESH: Biopsy, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, steatosis, MESH: Hepacivirus, MESH: Genetic Variation, MESH: Phylogeny, MESH: Fatty Liver, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Molecular Sequence Data, MESH: Conserved Sequence, electron microscopy, MESH: Host-Pathogen Interactions, MESH: Adult, MESH: Male, MESH: Hepatitis C, Chronic, HCV, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Viral Nonstructural Proteins, MESH: Female, MESH: Liver
Abstract: International audience; Most clinical studies suggest that the prevalence and severity of liver steatosis are higher in patients infected with hepatitis C virus (HCV) genotype 3 than in patients infected with other genotypes. This may reflect the diversity and specific intrinsic properties of genotype 3 virus proteins. We analyzed the possible association of particular residues of the HCV core and NS5A proteins known to dysregulate lipid metabolism with steatosis severity in the livers of patients chronically infected with HCV. We used transmission electron microscopy to quantify liver steatosis precisely in a group of 27 patients, 12 of whom were infected with a genotype 3 virus, the other 15 being infected with viruses of other genotypes. We determined the area covered by lipid droplets in liver tissues and analyzed the diversity of the core and NS5A regions encoded by the viral variants circulating in these patients. The area covered by lipid droplets did not differ significantly between patients infected with genotype 3 viruses and those infected with other genotypes. The core and NS5A protein sequences of the viral variants circulating in patients with mild or severe steatosis were evenly distributed throughout the phylogenic trees established from all the collected sequences. Thus, individual host factors seem to play a much greater role than viral factors in the development of severe steatosis in patients chronically infected with HCV, including those infected with genotype 3 viruses.
Published: 2012

76. Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury.: Notch-3 receptor and inflammatory kidney diseases

Author: Djudjaj, Sonja, Chatziantoniou, Christos, Raffetseder, Ute, Guerrot, Dominique, Dussaule, Jean-Claude, Boor, Peter, Kerroch, Monique, Hanssen, Lydia, Brandt, Sabine, Dittrich, Anne-Marie, Ostendorf, Tammo, Floege, Jürgen, Zhu, Cheng, Lindenmeyer, Maja, Cohen, Clemens, Mertens, Peter, Chatziantoniou, Christos, Department of Nephrology and Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH), Department of Nephrology and Hypertension, Diabetes and Endocrinology, Otto-von-Guericke-Universität Magdeburg = Otto-von-Guericke University [Magdeburg] (OVGU), Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pathology, Institute of Molecular Biomedicine, Comenius University in Bratislava, Department of Medical Microbiology, Division of nephrology and Institute of Physiology, Universität Zürich [Zürich] = University of Zurich (UZH), and This work was supported by fellowship grants from the ERA-ETDA (to S.D.), DFG SFB 854 project 01 (to P.R.M.) and DFG Sachbeihilfeantrag 1365/7-1 (to P.R.M.). C.C. received INSERM funding. U.R was funded by the Else-Kröner-Fresenius- Stiftung.
Subjects: MESH: Signal Transduction, MESH: Inflammation, MESH: Rats, proliferation, MESH: Receptor, Notch1, MESH: Mice, Knockout, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Biopsy, MESH: Mice, Inbred C57BL, MESH: Cell Proliferation, MESH: Up-Regulation, MESH: Animals, chemotaxis, MESH: Intercellular Signaling Peptides and Proteins, MESH: Mice, MESH: Transforming Growth Factor beta, Kidney diseases, MESH: Humans, urogenital system, fibrosis, MESH: Kidney, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Cell Line, tubular cells, inflammation, Notch receptors, MESH: Fibrosis, MESH: Membrane Proteins, MESH: Ureteral Obstruction, MESH: Disease Models, Animal, MESH: Nephritis, Interstitial, MESH: Receptors, Notch, MESH: Female
Abstract: International audience; Kidney diseases impart a vast burden on affected individuals and the overall health care system. Progressive loss of renal parenchymal cells and functional decline following injury are often observed. Notch-1 and -2 receptors are crucially involved in nephron development and contribute to inflammatory kidney diseases. We specifically determined the participation of receptor Notch-3 following tubulointerstitial injury and in inflammatory responses. Here we show by heat map analyses that Notch-3 transcripts are up-regulated in human kidney diseases. A similar response was corroborated with kidney cells following TGF-β exposure in vitro. The murine unilateral ureteral obstruction (UUO) model mirrors hallmarks of tubulointerstitial injury and damage. A subset of tubular and interstitial cells demonstrated up-regulated Notch-3 receptor expression in diseased animals. We hypothesized a relevance of Notch-3 receptors for the chemotactic response. To address this question, animals with genetic ablation of receptor Notch-3 were analysed following UUO. As a result, we found that Notch-3-deficient animals are protected from tubular injury and cell loss with significantly reduced interstitial collagen deposition. Monocytic cell infiltration was significantly reduced and retarded, likely due to abrogated chemokine synthesis. A cell model was set up that mimics enhanced receptor Notch-3 expression and activation. Here a pro-mitogenic response was seen with activated signalling in tubular cells and fibroblasts. In conclusion, Notch-3 receptor fulfils non-redundant roles in the inflamed kidney that may not be replaced by other Notch receptor family members. Thus, specific blockade of this receptor may be suitable as therapeutic option to delay progression of kidney disease.
Published: 2012

77. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil

Author: Antoine Thierry, Yannick Le Meur, Michel Delahousse, Yvon Lebranchu, Nacera Ouali, Denis Glotz, Stephanie Rouanet, Laeticia Albano, Michèle Kessler, Nailya Tagieva, Philippe Lang, François Glowacki, François Vrtovsnik, Maïté Jauréguy, Nassim Kamar, Valérie Garrigue, Jean-Philippe Rerolle, Lionel Couzi, Anne-Elisabeth Heng, Christiane Mousson, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHRU Brest - Service de Nephrologie (CHU - BREST - Nephrologie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Science et Technologie du Lait et de l'Oeuf (STLO), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Department of Nephrology, University Hospital, Lille, France., Department of Nephrology, University Hospital, Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Université de Limoges (UNILIM)-CHU Limoges, Department of Nephrology, Transplantation and Peritoneal Dialysis, University Hospital, Service de néphrologie et de transplantation rénale [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Nutrition Humaine (UNH), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Institut National de la Recherche Agronomique (INRA), Department of Nephrology and Transplantation, Foch Hospital, Department of Nephrology and Transplantation, University Hospital, Nice, Departement of Nephrology and Transplantation, University Hospital, Nice, Budapest University of Technology and Economics [Budapest] (BME), Department of Nephrology, Transplantation and Dialysis, Bordeaux, France, Department of Nephrology, Transplantation and Dialysis, Bordeaux, Department of Nephrology, University Hospital, Amiens, France, Department of Nephrology, University Hospital, Amiens, Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Néphrologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Néphrologie [Bichat - Claude Bernard], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Roche SAS, Neuilly-sur-Seine, France, Laboratoire Roche SAS, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Clermont Université-Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Recherche Agronomique (INRA), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Graft Rejection, Male, Biopsy, 030232 urology & nephrology, 030230 surgery, Kidney, MESH: Cyclosporine, MESH: Dose-Response Relationship, Drug, MESH: Kidney Transplantation, MESH: Biopsy, 0302 clinical medicine, Adrenal Cortex Hormones, Risk Factors, MESH: Risk Factors, Clinical endpoint, Prospective Studies, Prospective cohort study, MESH: Treatment Outcome, MESH: Middle Aged, medicine.diagnostic_test, MESH: Withholding Treatment, Middle Aged, 3. Good health, Treatment Outcome, Tolerability, Cyclosporine, Corticosteroid, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Immunosuppressive Agents, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, medicine.drug_class, Urology, MESH: Graft Rejection, Mycophenolic acid, MESH: Adrenal Cortex Hormones, 03 medical and health sciences, medicine, Humans, MESH: Mycophenolic Acid, Transplantation, MESH: Humans, Dose-Response Relationship, Drug, business.industry, MESH: Adult, MESH: Kidney, Mycophenolic Acid, Kidney Transplantation, MESH: Male, MESH: Prospective Studies, Discontinuation, Surgery, Regimen, Withholding Treatment, Therapeutic drug monitoring, Feasibility Studies, business, MESH: Feasibility Studies, MESH: Female
Abstract: International audience; Early posttransplant steroid withdrawal may increase the risk of acute rejection and the occurrence of subclinical acute rejection (SCAR). We assessed the feasibility and safety of early steroid withdrawal in low-risk patients receiving cyclosporine A (CsA) and the impact of optimization of mycophenolic acid exposure on steroid withdrawal success. De novo, low-immunological risk kidney recipients received an anti-interleukin-2-receptor-α antibody induction, a short course of 7 days of corticosteroids, and CsA with 2-hr postdose concentration monitoring. They were randomized to adjusted dose (AD) of mycophenolate mofetil (MMF) using therapeutic drug monitoring (TDM) or a fixed-dose (FD) regimen. MMF 3 g was initiated posttransplant and then adjusted starting at week 2 to a 0 to 12 hr area under the concentration time curve of 40 mg · h/L versus 2 g daily, respectively. The primary endpoint was a composite of the proportion of patients experiencing biopsy-proven acute rejection (BPAR) and those with SCAR identified on the 3-month protocol biopsy. Among 247 analyzed patients, only 22 in the AD group and 17 in the FD group experienced BPAR or SCAR (P=0.46). The rate of SCAR was low: 4% (AD) and 2.5% (FD). No between-group difference in the incidence of BPAR was observed. TDM yielded MMF doses ranging from 1 to 4 g/d and significantly reduced interpatient variability at weeks 26 and 52 in the AD group. In low-immunological risk kidney recipients, MMF combined with CsA allows early corticosteroid discontinuation with good tolerability. In this group of patients, TDM of MMF does not improve clinical outcome.
Published: 2011

78. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress]

Author: Bridoux, Franck, Delbes, Sébastien, Sirac, Christophe, Pourreau, François, Puyade, Matthieu, Desport, Estelle, Jaccard, Arnaud, Fermand, Jean-Paul, Touchard, Guy, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Service de néphrologie - hémodialyse et transplantation rénale, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP]
Subjects: MESH: Immunoglobulin Light Chains, Biopsy, Paraproteinemias, Kidney, Dexamethasone, MESH: Kidney Transplantation, Bortezomib, MESH: Biopsy, MESH: Melphalan, MESH: Paraproteinemias, Humans, MESH: Amyloidosis, Melphalan, MESH: Kidney Diseases, MESH: Humans, Plasma Exchange, MESH: Heart Transplantation, MESH: Kidney, Amyloidosis, MESH: Plasma Exchange, Boronic Acids, Kidney Transplantation, MESH: Pyrazines, MESH: Dexamethasone, Pyrazines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Heart Transplantation, MESH: Boronic Acids, Immunoglobulin Light Chains, Kidney Diseases, Immunoglobulin Heavy Chains, MESH: Immunoglobulin Heavy Chains
Abstract: International audience; Various renal disorders are associated with monoclonal gammopathies, secondary to tissue deposition or precipitation of a monoclonal immunoglobulin (Ig) or a fragment thereof (isolated Ig light chain or heavy chain). They are classified according to the localization of renal lesions, either glomerular or tubular and to the pattern of ultrastructural organization of Ig deposits. Renal disease in monoclonal gammopathies may be isolated, or associated with various systemic symptoms particularly in AL amyloidosis, Randall-type monoclonal Ig deposition disease and monoclonal cryoglobulinemias. Except for myeloma cast nephropathy, which occurs in the setting of high-mass myeloma and is recognized after electrophoretic analysis of proteinuria and AL amyloidosis, which diagnosis is usually made after pathological examination of non-invasive tissue specimens (i.e. abdominal fat or minor salivary glands), a kidney biopsy is required to identify the other types of renal disorders associated with monoclonal gammopathies and to estimate renal prognosis. Renal pathological diagnosis is difficult and relies on careful examination of kidney biopsy samples, by light microscopy, immunofluorescence studies using conjugates specific for Ig light and heavy chains, IgG sub-classes and heavy chain constant domains and by electron microscopy. In some cases, additional studies are required to identify the nature of deposits, such as immuno-electron microscopy or mass spectrometric-based proteomic analysis after laser dissection. In patients with renal disorders related to Ig light chain precipitation or deposition (myeloma cast nephropathy, AL amyloidosis, Randall-type light chain deposition disease), measurement of serum free light chains at baseline and throughout follow-up is mandatory to evaluate clonal response to chemotherapy. A more than or equal to 50% decrease in serum free light chain levels is associated with increased renal and patient survival. In AL amyloidosis, serum levels of markers of cardiac disease (NT-proBNP and troponin) are also closely associated with prognosis. Efficient chemotherapy, tailored to the underlying plasma cell or lymphoproliferative disorder and adapted to renal function, should be promptly introduced, even in the absence of overt malignant haematological disease. Renal prognosis and patient survival (particularly in AL amyloidosis and cast nephropathy) are closely associated with the rapid achievement of an haematological response. The combination of melphalan plus dexamethasone (MDex) is currently used as first-line chemotherapy in systemic AL amyloidosis. Bortezomib-based regimens are commonly employed as first-line treatment in myeloma cast nephropathy and Randall-type monoclonal Ig deposition disease and as second line therapy in AL amyloidosis patients with advanced cardiomyopathy or refractory to previous chemotherapy. Solid organ transplantation (heart and kidney) should be considered in patients with AL amyloidosis or Randall-type monoclonal Ig deposition disease and advanced cardiac or renal failure. Prolonged graft and patient survival may be obtained, providing that recipients do not have other severe organ involvement or symptomatic myeloma and that haematological remission has been achieved with chemotherapy before or after organ transplantation.
Published: 2011

79. [Renal biopsy practice: results of a French study and recommendations]

Author: Bollée , Guillaume, Moulin , Bruno, Martinez , Frank, Meulders , Quentin, Rougier , Jean-Philippe, Baumelou , Alain, Glotz , Denis, Subra , Jean-François, Ulinski , Tim, Vrigneaud , Laurence, Brasseur , José, Alhenc-Gelas , Martine, Martin , Laurent, DANIEL , Laurent, Kourilsky , Olivier, Deteix , Patrice, Sie , Pierre, Ronco , Pierre, Houillier , Pascal, Laboratoire de Recherche en Imagerie : Méthodes d'imagerie des Échanges transcapillaires (LRI - EA4062), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie et Transplantation, CHU Strasbourg, Service de Transplantation Rénale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie [Avignon], Centre Hospitalier Henri Duffaut (Avignon), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Service de Néphrologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de Néphrologie [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), CHU Trousseau [APHP], Service de Néphrologie [Valenciennes], Centre Hospitalier de Valenciennes, Service de Néphrologie [Bois-Bernard], Hôpital privé Bois-Bernard, Service d'Hématologie [Georges-Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), Service de Pathologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire d'Anatomopathologie [Aix-Marseille], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Néphrologie [Evry], Centre Hospitalier Sud Francilien, Service de Néphrologie [Clermont-Ferrand], CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de Physiologie [Georges-Pompidou], Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Néphrologie [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CH Evry-Corbeil-CH Evry-Corbeil, Laboratoire d'Hématologie [Rangueil], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], RONCO, Pierre, Service de Département de Néphrologie = Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de néphrologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Laboratoire de Recherche en Imagerie : Méthodes d'imagerie des Échanges transcapillaires ( LRI - EA4062 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université d'Angers ( UA ) -CHU Angers, Service de Néphrologie Pédiatrique [Trousseau], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I ( UdA ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, and CHU Toulouse [Toulouse]
Subjects: MESH: Kidney Diseases, MESH: Humans, Biopsy, MESH : Humans, MESH: Kidney, Kidney, MESH : Kidney, MESH: France, MESH: Biopsy, MESH : Physician's Practice Patterns, [ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], MESH : Biopsy, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], MESH : Kidney Diseases, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Humans, Kidney Diseases, France, Practice Patterns, Physicians', MESH : France, MESH: Physician's Practice Patterns
Abstract: International audience; BACKGROUND: Although several risk factors associated with complications after renal biopsy (RB) have been identified, recommendations for RB procedures are still lacking. Our working group, appointed by the scientific commission of the Société de néphrologie in France, aimed to depict the main aspects of the practice of RB in adults in France, before establishing some guidelines. METHODS: Members of the Société de néphrologie in France were asked to participate to a questionnaire survey on RB procedures. RESULTS: Eighty-eight nephrologists from 74 units (27 in teaching hospitals, 35 in public general hospitals, and 12 in private centers) participated in our study. Native kidney and graft biopsies were performed in 73 and 35 units, respectively. RB activity was highly variable among units, ranging from several hundred to less than ten per year. Transjugular RB was judged to be smoothly accessible in 28 out of 73 units (38.4%). Significant variations in practices were observed regarding patient information before RB, assessment of hemorrhagic risk factors, care of patients with antiplatelet agents and hemorrhagic risk factors, and radiological guidance. Early discharge (
Published: 2011

80. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years

Author: Martine Ropert, Yiyun Zhang, Pierre Brissot, Louis Griffel, John B. Porter, Vanessa Giannone, M. Domenica Cappellini, Yves Deugnier, Bruno Turlin, Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service des maladies du foie, departement de pathologie, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Centre de Référence des surcharges en Fer rares d'origine génétique, Laboratoire de Biochimie Pharmaceutique, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Novartis Pharmaceuticals, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], CHU Pontchaillou [Rennes], and Université de Rennes (UR)
Subjects: Liver Cirrhosis, Male, Pathology, Liver Iron Concentration, Cirrhosis, Time Factors, Thalassemia, Biopsy, medicine.disease_cause, Gastroenterology, Benzoates, Severity of Illness Index, Liver disease, MESH: Biopsy, 0302 clinical medicine, Fibrosis, MESH: Child, Child, MESH: Treatment Outcome, MESH: Iron, Cross-Over Studies, MESH: Middle Aged, Liver Disease, Alanine Transaminase, MESH: beta-Thalassemia, Middle Aged, Hepatitis C, Clinical Trial, 3. Good health, Deferoxamine, Treatment Outcome, Liver, MESH: Young Adult, 030220 oncology & carcinogenesis, Child, Preschool, Female, MESH: Liver Cirrhosis, MESH: Benzoic Acids, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Hepatitis C virus, Iron, MESH: Ferritins, Iron Chelating Agents, MESH: Cross-Over Studies, 03 medical and health sciences, Young Adult, Internal medicine, MESH: Severity of Illness Index, medicine, Humans, MESH: Adolescent, MESH: Hepatitis C, MESH: Humans, Hepatology, business.industry, Deferasirox, beta-Thalassemia, MESH: Time Factors, MESH: Child, Preschool, MESH: Biological Markers, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Triazoles, medicine.disease, MESH: Male, MESH: Triazoles, MESH: Iron Chelating Agents, MESH: Alanine Transaminase, Ferritins, Therapy, business, MESH: Female, Biomarkers, 030215 immunology, MESH: Liver
Abstract: International audience; BACKGROUND & AIMS: Most data on the effects of iron chelation therapy for patients with liver fibrosis come from small studies. We studied the effects of the oral iron chelator deferasirox on liver fibrosis and necroinflammation in a large population of patients with iron overload β-thalassemia. METHODS: We studied data from 219 patients with β-thalassemia, collected from histologic analyses of biopsy samples taken at baseline and after at least 3 years of treatment with deferasirox. Treatment response was assessed from liver iron concentrations at baseline and the end of the study. Liver fibrosis, necroinflammation, and markers of iron overload and liver enzymes were recorded. Patients were also assessed, by serologic analysis at baseline, for hepatitis C virus infection. RESULTS: By the end of the study, stability of Ishak fibrosis staging scores (change of -1, 0, or +1) or improvements (change of ≤-2) were observed in 82.6% of patients; Ishak necroinflammatory scores improved by a mean value of -1.3 (P
Published: 2011

81. Altered expression of the gap junction protein connexin43 is associated with papillary thyroid carcinomas when compared with other noncancer pathologies of the thyroid

Author: Sophie Crespin, Lucie Karayan-Tapon, Gauthier Bouche, Anne Cantereau, Thibault Desurmont, Claudia Dominguez, Gaëlle Fromont, Marc Mesnil, Hélène Gibelin, Pierre Levillain, Jean-Louis Kraimps, Service de chirurgie viscérale et endocrinienne, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Cellules souches leucémiques et thérapeuthiques, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut de physiologie et biologie cellulaires (IPBC), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Service d'Anatomie et de Cytologie Pathologiques [Poitiers], Laboratoire d'Anatomo-Pathologie, CHU de Poiters, Department of Public Health, Modèles de Cellules Souches Malignes et Thérapeutiques, and Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: MESH: Carcinoma, Pathology, Thyroiditis, Goiter, endocrine system diseases, MESH: Thyroiditis, Endocrinology, Diabetes and Metabolism, Biopsy, [SDV]Life Sciences [q-bio], MESH: Gap Junctions, Thyroid Gland, MESH: Graves Disease, MESH: Down-Regulation, MESH: Biopsy, 0302 clinical medicine, Endocrinology, MESH: Microscopy, Confocal, Thyroid cancer, Tissue homeostasis, MESH: Goiter, Nodular, 0303 health sciences, Microscopy, Confocal, medicine.diagnostic_test, Thyroid, Gap Junctions, Graves Disease, 3. Good health, medicine.anatomical_structure, Thyroid Cancer, Papillary, MESH: Thyroid Neoplasms, 030220 oncology & carcinogenesis, cardiovascular system, Immunohistochemistry, biological phenomena, cell phenomena, and immunity, Goiter, Nodular, medicine.medical_specialty, endocrine system, Down-Regulation, Biology, Immunofluorescence, Thyroid carcinoma, 03 medical and health sciences, medicine, Biomarkers, Tumor, Humans, RNA, Messenger, Thyroid Neoplasms, 030304 developmental biology, Retrospective Studies, MESH: RNA, Messenger, MESH: Humans, Carcinoma, MESH: Retrospective Studies, medicine.disease, Carcinoma, Papillary, MESH: Connexin 43, MESH: Thyroid Gland, Connexin 43, MESH: Tumor Markers, Biological, sense organs
Abstract: International audience; BACKGROUND: Gap junctions are membrane structures composed of connexins (Cx) that allow diffusion of small molecules between cells. They are involved in tissue homeostasis, and various organ dysfunctions have been associated with gap junction defects. To verify their possible involvement in thyroid pathologies, the expression of connexin43 (Cx43), the major Cx in the human thyroid, was evaluated in a variety of diseases including cancer. METHODS: There were 122 samples from various thyroid pathologies that were collected to analyze the presence of Cx43 by immunofluorescence. Through confocal microscopy, different patterns of Cx43 localization were identified as normal (membrane) or abnormal (cytoplasmic or lack of detection). The analysis of Cx43 expression was further performed by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry in a subset of 25 papillary carcinomas and compared with nontumoral thyroid tissues. RESULTS: The presence of Cx43 was commonly altered in thyroid cancer, as abnormal Cx43 staining was detected in 94.1% of cancer, 47.4% of adenomas, 45.7% of multinodular goiter, 16.7% of Graves' disease, and 25% of thyroiditis. In papillary carcinoma samples, the deregulation of Cx43 expression was mostly the consequence of a decrease of Cx43 mRNA (68% of cases) when compared with normal tissue. When Cx43 mRNA was not downregulated (32% of cases), both loss of membrane staining and aberrant cytoplasmic distribution of the protein were observed. CONCLUSIONS: These results show that aberrations of Cx43 expression are associated with thyroid papillary carcinoma.
Published: 2011

82. EMMPRIN (CD147) regulation of MMP-9 in bronchial epithelial cells in COPD

Author: Jouneau, Stephane, Khorasani, Nadia, de Souza, Patricia, Macedo, Patricia, Zhu, Jie, Bhavsar, Pankaj K, Chung, Kian F, Imperial College London, Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de pneumologie [Rennes] = Pneumology [Rennes], CHU Pontchaillou [Rennes], CHU de Rennes, Université de Rennes 1, France- 'Pneumologie développement'- SPLF (Société de Pneumologie de Langue Française)- Imperial College Trust Fund, UK, and Université de Rennes (UR)
Subjects: Adult, Lipopolysaccharides, Male, MESH: Smoking, matrix metalloproteinase, MESH: Macrophages, Alveolar, Adolescent, Biopsy, Bronchi, MESH: Pulmonary Disease, Chronic Obstructive, extracellular matrix metalloproteinase inducer, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, chronic obstructive pulmonary disease, Pulmonary Disease, Chronic Obstructive, Young Adult, MESH: Biopsy, MESH: Antigens, CD147, Macrophages, Alveolar, bronchial epithelial cell, MESH: Antibodies, Blocking, MESH: C-Reactive Protein, Humans, Antibodies, Blocking, Cells, Cultured, MESH: Adolescent, MESH: Humans, Smoking, MESH: Bronchi, Epithelial Cells, MESH: Adult, MESH: Matrix Metalloproteinase 9, MESH: Male, respiratory tract diseases, MESH: Leukocytes, Mononuclear, C-Reactive Protein, Matrix Metalloproteinase 9, MESH: Young Adult, MESH: Epithelial Cells, Basigin, Leukocytes, Mononuclear, Female, alveolar macrophage, MESH: Lipopolysaccharides, MESH: Female, MESH: Cells, Cultured
Abstract: International audience; BACKGROUND AND OBJECTIVE: Extracellular matrix metalloproteinase inducer (EMMPRIN or CD147) induces the production of matrix metalloproteinases (MMP) such as MMP-9, which plays an important role in COPD. We determined its cellular origin and role in MMP-9 production in COPD. METHODS: Bronchial biopsies, alveolar macrophages (AM) and blood monocytes (BM) from patients with COPD, healthy smokers and non-smokers, and bronchial epithelial cells (EC) from surgically resected airways from patients with COPD were stimulated with LPS or CRP in the presence and absence of an anti-EMMPRIN blocking antibody. EMMPRIN in BAL, plasma, conditioned media and cell lysates was quantified and immunohistochemical localization of EMMPRIN was determined in bronchial biopsies. MMP-9 activity and mRNA was also determined. RESULTS: EMMPRIN levels in BAL fluid were higher in patients with COPD compared with non-smokers and smokers. There was greater EMMPRIN expression in EC from patients with COPD compared with smokers and non-smokers. EC secreted and expressed more EMMPRIN protein than BM and AM. Blocking EMMPRIN decreased MMP-9 activity in supernatant of EC, but not in those from AM and BM, and decreased MMP-9 mRNA expression in EC. CONCLUSIONS: The increased EMMPRIN expression in COPD is reflected by an increased release from bronchial EC, which are one of the main source of EMMPRIN. EMMPRIN regulates MMP-9 expression in COPD.
Published: 2011

83. Mitochondrial abnormalities in patients with HIV-HCV co-infection as compared to patients with HCV mono-infection

Author: Bruno Turlin, Faouzi Souala, Cédric Arvieux, Christian Michelet, Dominique Guyader, Pierre Rochcongar, Pierre Tattevin, Jocelyne Beillot, Jean-Marc Begue, Jean-Marc Chapplain, Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Microenvironnement et remodelage, Centre Hospitalier Universitaire [Rennes]-Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Foie, métabolismes et cancer, the COREC (COmité de la REcherche Clinique), Centre Hospitalo-Universitaire de Rennes, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: Male, hepatitis C virus, MESH: Histocytochemistry, Biopsy, HIV Infections, Mitochondria, Liver, Hepacivirus, Mitochondrion, medicine.disease_cause, Gastroenterology, Incremental exercise, Nucleoside Reverse Transcriptase Inhibitor, MESH: Linear Models, MESH: Biopsy, 0302 clinical medicine, Liver Function Tests, cytochrome c oxidase, MESH: Liver Function Tests, Medicine, Pharmacology (medical), MESH: Hepacivirus, 030212 general & internal medicine, MESH: Oxygen Consumption, MESH: Middle Aged, medicine.diagnostic_test, Histocytochemistry, MESH: HIV, Respiratory chain complex, virus diseases, MESH: HIV Infections, Middle Aged, Hepatitis C, 3. Good health, mitochondria, Infectious Diseases, Liver biopsy, Lactates, Female, 030211 gastroenterology & hepatology, MESH: Mitochondria, Liver, Anaerobic exercise, Adult, medicine.medical_specialty, respiratory chain reaction, Hepatitis C virus, exercise test, MESH: Lactates, 03 medical and health sciences, Oxygen Consumption, MESH: Cross-Sectional Studies, Internal medicine, Humans, MESH: Hepatitis C, MESH: Humans, business.industry, HIV, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Virology, MESH: Male, Cross-Sectional Studies, Linear Models, business, Complication, MESH: Female
Abstract: International audience; INTRODUCTION: Mitochondrial dysfunction is a classic complication of HIV infection and its treatment and has also been reported in hepatitis C virus (HCV)-infected patients. Little is known about interactions between both viruses on mitochondrial metabolism. METHODS: We performed a cross-sectional study of HCV-infected patients who underwent liver biopsy as part of their routine care. Mitochondrial function was assessed by (a) liver morphological (histology) and functional (spectro-photometry) studies, and (b) serum lactate kinetics, oxygen uptake, and anaerobic threshold measurement during standardized incremental exercise. Three predefined groups of patients were compared. RESULTS: Thirty-eight HCV-infected patients were included: 13 not HIV infected (group 1), 7 with HIV co-infection and low nucleoside reverse transcriptase inhibitor (NRTI) exposure (none over the last 2 years; group 2), and 18 with HIV co-infection and high NRTI exposure (group 3). On liver biopsies, respiratory chain complex IV activity was impaired, at 5 (2-7) nmol/min/mg substrates in group 1, 5 (3-8) in group 2, and 8 (2-13) in group 3 (normal values, 20-56). Maximal power output was diminished and anaerobic threshold occurred earlier in HIV-infected patients, regardless of NRTI exposure. CONCLUSION: HCV has deleterious effects on liver mitochondrial metabolism, notably on respiratory chain complex IV. No significant interaction with HIV was observed.
Published: 2011

84. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients

Author: P, Miailhes, P, Pradat, M, Chevallier, K, Lacombe, F, Bailly, L, Cotte, M-A, Trabaud, A, Boibieux, J, Bottero, C, Trepo, F, Zoulim, Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Equipe 16, Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Institut de recherche en astrophysique et planétologie (IRAP), Institut national des sciences de l'Univers (INSU - CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Adult, Liver Cirrhosis, Male, Hepatitis B virus, Biopsy, HIV Infections, MESH: Algorithms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Elasticity Imaging Techniques, MESH: HIV-1, Young Adult, MESH: Biopsy, Humans, MESH: Middle Aged, MESH: Humans, MESH: Hepatitis B, MESH: Adult, MESH: HIV Infections, Middle Aged, Hepatitis B, MESH: Male, MESH: Hepatitis B virus, Liver, MESH: Young Adult, HIV-1, Elasticity Imaging Techniques, Female, MESH: Liver Cirrhosis, MESH: Female, Algorithms, MESH: Liver
Abstract: International audience; Transient elastography (TE) is a noninvasive technique to evaluate liver fibrosis. We compared the performance of TE with liver biopsy (LB) in patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection. Patients prospectively underwent TE and LB. The diagnosis accuracy of TE was calculated using receiver operating characteristic (ROC) curves for different stages of fibrosis, and optimal cut-off values were defined. A sequential algorithm combining TE with biochemical score (Fibrotest) is proposed. Fifty-seven patients had both TE and LB (median time: 3 days) and two with proven cirrhosis, only TE. Forty-six (78%) were under antiretroviral therapy with anti-HBV drugs in 98%, and 19 (32%) had elevated alanine aminotransferase (ALT). A significant correlation was observed between liver stiffness measurement (LSM) and METAVIR fibrosis stages (P < 0.0001). Patients with elevated ALT tended to have higher LSM than those with normal ALT. The areas under the ROC curves were 0.85 for significant fibrosis (≥ F2), 0.92 for advanced fibrosis (≥ F3) and 0.96 for cirrhosis. Using a cut-off of 5.9 kPa for F ≥ 2 and 7.6 kPa for F ≥ 3, the diagnosis accuracy was 83% and 86%, respectively. With an algorithm combining TE and Fibrotest, 97% of patients were well classified for significant fibrosis. Using this algorithm, the need for LB can be reduced by 67%. In HIV/HBV-coinfected patients, most of them with normal ALT under antiretroviral treatment including HBV active drugs, TE was proficient in discriminating moderate to severe fibrosis from minimal liver disease.
Published: 2011

85. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice

Author: Eric Giang, Jacques Belghiti, Serban Morosan, Sophie Berissi, Céline Lamant, Johan Neyts, Eva Wimmer, Gherard Puerstinger, Patrick Soussan, Lucie DaSilva, Olivier Hantz, Marie-Noëlle Brunelle, Laurent Hannoun, Dina Kremsdorf, Hélène Massinet, Nicolas Brezillon, IFR Laennec (IL), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), neuroscience and barin technology, Service de chirurgie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Microbiology and Immunology, Rega Institute for Medical Research, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), equipe 16, Physiopathologie moléculaire et nouveaux traitements des hépatites virales, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR62-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR62-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Carcinogenèse Hépatique et Virologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM), Pathogénèse des Hépatites Virales B et Immunothérapie (UMR_S 812), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), IFR Laennec ( IL ), Institut National de la Recherche Agronomique ( INRA ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Beaujon, Service de chirurgie digestive et hépato-bilio-pancréatique [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Catholic University of Leuven ( KU Leuven ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-IFR62-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-IFR62-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Pathogénèse des Hépatites Virales B et Immunothérapie ( UMR_S 812 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université de Lyon-Université de Lyon-IFR62-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Cancérologie de Lyon (CRCL), and Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Mouse, Pyridines, Gastroenterology and hepatology, Biopsy, medicine.medical_treatment, MESH : Immunohistochemistry, MESH : Pyrimidines, MESH : Hepatitis B virus, MESH : Viral Load, Mice, SCID, MESH : Hepatocytes, Liver transplantation, medicine.disease_cause, Hepatitis, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Hepatocytes, Mice, MESH: Biopsy, 0302 clinical medicine, MESH : Albumins, MESH: Animals, MESH : DNA, Viral, MESH: Mice, SCID, 0303 health sciences, Multidisciplinary, MESH: Kinetics, virus diseases, Animal Models, Viral Load, Hepatitis B, Antivirals, Immunohistochemistry, 3. Good health, MESH : Antiviral Agents, Infectious hepatitis, MESH: Hepatitis B virus, Real-time polymerase chain reaction, Liver, Capsid, 030220 oncology & carcinogenesis, Infectious diseases, Medicine, MESH : Kinetics, MESH: Viral Load, Viral load, Research Article, MESH: Antiviral Agents, Hepatitis B virus, MESH : Pyridines, Science, Alpha interferon, Viremia, [SDV.CAN]Life Sciences [q-bio]/Cancer, Viral diseases, Biology, Antiviral Agents, Microbiology, 03 medical and health sciences, Model Organisms, Albumins, Virology, MESH : Mice, medicine, Animals, Humans, MESH: Mice, Liver diseases, 030304 developmental biology, MESH: Humans, MESH: Hepatitis B, MESH : Humans, MESH: Pyridines, MESH : Liver, MESH : Hepatitis B, MESH: Immunohistochemistry, medicine.disease, MESH : Mice, SCID, digestive system diseases, MESH: DNA, Viral, Kinetics, Animal Models of Infection, Pyrimidines, Viral replication, MESH : Biopsy, MESH: Pyrimidines, DNA, Viral, Immunology, Hepatocytes, MESH : Animals, MESH: Albumins, MESH: Liver
Abstract: International audience; Current treatments for HBV chronic carriers using interferon alpha or nucleoside analogues are not effective in all patients and may induce the emergence of HBV resistant strains. Bay 41-4109, a member of the heteroaryldihydropyrimidine family, inhibits HBV replication by destabilizing capsid assembly. The aim of this study was to determine the antiviral effect of Bay 41-4109 in a mouse model with humanized liver and the spread of active HBV. Antiviral assays of Bay 41-4109 on HepG2.2.15 cells constitutively expressing HBV, displayed an IC(50) of about 202 nM with no cell toxicity. Alb-uPA/SCID mice were transplanted with human hepatocytes and infected with HBV. Ten days post-infection, the mice were treated with Bay 41-4109 for five days. During the 30 days of follow-up, the HBV load was evaluated by quantitative PCR. At the end of treatment, decreased HBV viremia of about 1 log(10) copies/ml was observed. By contrast, increased HBV viremia of about 0.5 log(10) copies/ml was measured in the control group. Five days after the end of treatment, a rebound of HBV viremia occurred in the treated group. Furthermore, 15 days after treatment discontinuation, a similar expression of the viral capsid was evidenced in liver biopsies. Our findings demonstrate that Bay 41-4109 displayed antiviral properties against HBV in humanized Alb-uPA/SCID mice and confirm the usefulness of Alb-uPA/SCID mice for the evaluation of pharmaceutical compounds. The administration of Bay 41-4109 may constitute a new strategy for the treatment of patients in escape from standard antiviral therapy.
Published: 2011

86. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies

Author: Ram-Wolff, Caroline, Martin-Garcia, Nadine, Bensussan, Armand, Bagot, Martine, Ortonne, Nicolas, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: MESH: Immunophenotyping, MESH: Antigens, CD3, MESH: Dermatitis, Exfoliative, MESH: Paraffin Embedding, MESH: beta Catenin, ß-catenin, MESH: Phenotype, JunB, MESH: Biopsy, MESH: Aged, 80 and over, MESH: Skin, MESH: Diagnosis, Differential, hemic and lymphatic diseases, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Dermatitis, MESH: Aged, MESH: Psoriasis, MESH: Humans, MESH: Middle Aged, integumentary system, MESH: Proto-Oncogene Proteins c-jun, erythroderma, MESH: Skin Neoplasms, MESH: Adult, MESH: Retrospective Studies, MESH: Male, MESH: Predictive Value of Tests, MESH: France, MESH: Eczema, Sézary syndrome, CD30, MESH: Sezary Syndrome, histopathology, MESH: Drug Eruptions, MESH: Lymphocytes, MESH: Antigens, CD8, MESH: Female
Abstract: International audience; Erythroderma may be secondary to a cutaneous T-cell lymphoma (CTCL) and various other erythrodermic inflammatory dermatoses (EID), and their histopathologic distinction is often difficult. The aim of this study was to determine if morphological parameters, namely: the presence of b-catenin, and JunB (previously shown to be expressed by CTCL cells), the epidermal CD8:CD3 ratio, and CD30 expression may help in the histopathologic diagnosis of erythroderma, especially in differentiating CTCL and EID. We retrospectively reviewed a series of 47 skin biopsies from patients with erythroderma (18 CTCL and 29 EID). The diagnosis of each case was established using clinical, biological and histopathologic data. After a blind assessment of the hematoxylin--eosin--safran stained slides, a correct diagnosis of the underlying cause of erythroderma was made only in 31% of cases. A correct differential diagnosis between lymphoma and EID was done with certainty in 57% of cases. Various morphologic and phenotypic parameters were then recorded and we compared their frequency in the CTCL versus the EID group. With the exception of atypical lymphocytes, the moderate to high density of dermal infiltrates and Pautrier microabcesses, only found in CTCL, no morphologic parameter was found to be specific of CTCL, although single lymphocytes epidermotropism, telangiectasias, and slight lymphocytic dermal infiltrate were significantly more frequent in EID. A low (
Published: 2010

87. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies.: Histopathological diagnosis of erythroderma

Author: Ram-Wolff, Caroline, Martin-Garcia, Nadine, Bensussan, Armand, Bagot, Martine, Ortonne, Nicolas, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Guellaen, Georges
Subjects: MESH: Immunophenotyping, MESH: Antigens, CD3, MESH: Dermatitis, Exfoliative, MESH: Paraffin Embedding, MESH: beta Catenin, ß-catenin, MESH: Phenotype, JunB, MESH: Biopsy, MESH: Aged, 80 and over, MESH: Skin, MESH: Diagnosis, Differential, hemic and lymphatic diseases, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Dermatitis, MESH: Aged, MESH: Psoriasis, MESH: Humans, MESH: Middle Aged, integumentary system, MESH: Proto-Oncogene Proteins c-jun, erythroderma, MESH: Skin Neoplasms, MESH: Adult, MESH: Retrospective Studies, MESH: Male, MESH: Predictive Value of Tests, MESH: France, MESH: Eczema, Sézary syndrome, CD30, MESH: Sezary Syndrome, histopathology, MESH: Drug Eruptions, MESH: Lymphocytes, MESH: Antigens, CD8, MESH: Female
Abstract: International audience; Erythroderma may be secondary to a cutaneous T-cell lymphoma (CTCL) and various other erythrodermic inflammatory dermatoses (EID), and their histopathologic distinction is often difficult. The aim of this study was to determine if morphological parameters, namely: the presence of b-catenin, and JunB (previously shown to be expressed by CTCL cells), the epidermal CD8:CD3 ratio, and CD30 expression may help in the histopathologic diagnosis of erythroderma, especially in differentiating CTCL and EID. We retrospectively reviewed a series of 47 skin biopsies from patients with erythroderma (18 CTCL and 29 EID). The diagnosis of each case was established using clinical, biological and histopathologic data. After a blind assessment of the hematoxylin--eosin--safran stained slides, a correct diagnosis of the underlying cause of erythroderma was made only in 31% of cases. A correct differential diagnosis between lymphoma and EID was done with certainty in 57% of cases. Various morphologic and phenotypic parameters were then recorded and we compared their frequency in the CTCL versus the EID group. With the exception of atypical lymphocytes, the moderate to high density of dermal infiltrates and Pautrier microabcesses, only found in CTCL, no morphologic parameter was found to be specific of CTCL, although single lymphocytes epidermotropism, telangiectasias, and slight lymphocytic dermal infiltrate were significantly more frequent in EID. A low (
Published: 2010

88. Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjögren's syndrome

Author: Laurent Misery, Gabriel J. Tobón, Pierre Youinou, Gilles Lemasson, Valérie Devauchelle, Anne-Marie Roguedas, Alain Saraux, Jacques-Olivier Pers, Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Laboratoire d'Immunologie et Immunothérapie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Michel, Geneviève
Subjects: Systemic disease, Pathology, Biopsy, Salivary Glands, MESH: Biopsy, Cell Movement, Immunopathology, Immunology and Allergy, Medicine, Memory B cell, MESH: Antigens, CD, MESH: Cell Movement, Skin, CD20, MESH: Aged, B-Lymphocytes, MESH: Middle Aged, medicine.diagnostic_test, biology, integumentary system, Anatomical pathology, Cell Differentiation, Middle Aged, Sjogren's Syndrome, MESH: Immunologic Memory, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Adult, MESH: Cell Differentiation, medicine.medical_specialty, MESH: Salivary Glands, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Sweat Glands, Immunology, MESH: Skin, Antigens, CD, MESH: B-Lymphocytes, Humans, Aged, MESH: Humans, business.industry, MESH: Adult, medicine.disease, Sweat Glands, MESH: Sjogren's Syndrome, Skin biopsy, biology.protein, Histopathology, business, Immunologic Memory, MESH: Female
Abstract: International audience; There is a crucial need for reliable diagnostic criteria for SS. Our objective was to evaluate the frequency of xerosis in patients with primary Sjögren's syndrome (SS), and compare histopathology of cutaneous sweat glands and labial salivary glands (LSGs), with respect to their contribution to the diagnosis. Twenty-two patients with primary SS and 22 matched normal volunteers were invited to rate their skin dryness on a visual analog scale. The skin was dryer (58.3 ± 10.1 versus 38.9 ± 7.6, P < 0.01), and xerosis more frequent (9 of 22 versus 2 of 22, P < 0.02) in the patients than in the controls. The axilla skin was chosen for a 6-mm punch biopsy. Lymphocytic infiltration was seen in the skin of 8 of the 12 patients tested. Two of them had normal LSGs. Most interestingly, B cell infiltrates were identified in patients' skin infiltrates, so that their presence might be a clue to the diagnosis of primary SS. These cell aggregates associated memory CD10-/CD20+/CD27+/IgD- B lymphocytes and immature CD20+/CD24 + lymphocytes. These latter findings strongly suggest that skin biopsies warrant inclusion into the routine clinical care of patients suspected of suffering from primary SS.
Published: 2010

89. Usefulness of the cytology in the diagnosis of bone lesions

Author: Sandrine Jousse-Joulin, Françoise Charles-Petillon, Alain Saraux, Johanne Morvan, Valérie Devauchelle-Pensec, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire de Cytologie, Brest, Laboratoire de Cytologie, Immunologie et Pathologie (EA2216), and Université de Brest (UBO)-IFR148
Subjects: Male, Lung Neoplasms, Biopsy, MESH: Biopsy, 0302 clinical medicine, MESH: Aged, 80 and over, Cytology, MESH: Cytological Techniques, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Histological Techniques, MESH: Carcinoma, Squamous Cell, Middle Aged, 030224 pathology, University hospital, MESH: Bone Neoplasms, 3. Good health, MESH: Young Adult, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Radiology, MESH: Bone Diseases, Bone Diseases, Bone biopsy, Adult, Tissue architecture, medicine.medical_specialty, Adolescent, Cytological Techniques, Bone Neoplasms, MESH: Histological Techniques, Adenocarcinoma, Malignancy, 03 medical and health sciences, Young Adult, Rheumatology, medicine, Humans, Aged, Retrospective Studies, MESH: Adolescent, MESH: Humans, business.industry, MESH: Adenocarcinoma, Histology, MESH: Retrospective Studies, MESH: Adult, medicine.disease, MESH: Male, MESH: Lung Neoplasms, Bone lesion, business, MESH: Female
Abstract: Objective This study aims to evaluate the interest to systematically combine cytology and histology for all bone specimens. Methods We reviewed all the bone biopsies performed in the University Hospital of Brest, France, between January 2000 and March 2008 and for which cytology and histology, obtained at the same time, were available. The interest of cytology and histology, alone and in combination was studied in comparison with the diagnostic made by the practitioner who treated the patient, which was considered the reference. Results Seventy patients were included. Among them, 55 had a final diagnosis of cancer. Thirty-nine of them were identified either by cytology or histology: twenty-five were identified by the two techniques, eight only by histology, and six only by cytology. There was no false-positive result, but false-negative results occurred with cytology (n = 3) and histology (n = 4). The agreement malignancy/benignancy was high (κ = 0.84) between cytology and histology when taking into account the only contributive results. It dropped to 0.52 when taking into account all the samples. Conclusion Cytology and histology are complementary to each other in diagnosing bone lesion. Combining cytomorphology and tissue architecture increases the accuracy of bone sample and would systematically be performed for each bone biopsy.
Published: 2010

90. Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians

Author: Bruno Landi, Marc Giovannini, Rosine Guimbaud, Bertrand Napoleon, Olivier Bouché, Anne Berger, Laurent Palazzo, Sylvie Bonvalot, Christian Boustière, Geneviève Monges, Jean-François Emile, Axel Le Cesne, Thomas Aparicio, Jean-Yves Blay, Bruno Buecher, Coindre Jm, Thierry Lecomte, Jean-Alain Chayvialle, Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims ( CHU Reims ), Département d'oncologie médicale, Institut Claudius Regaud, Service de Gastro-entérologie [Avicenne], Université Paris 13 ( UP13 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, Assistance Publique-Hopitaux de Paris, Centre d'Investigation Clinique en Biotherapie des cancers ( CIC 1428 , CBT 507 ), Institut Gustave Roussy ( IGR ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Génétique Oncologique, INSTITUT CURIE, Equipe 11, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Service d'Oncologie Médicale, Centre Léon Bérard [Lyon], Laboratoire épidémiologie et oncogénèse des tumeurs digestives, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Department of Endoscopy, Université de la Méditerranée - Aix-Marseille 2, Génétique, Immunothérapie, Chimie et Cancer ( GICC ), Université de Tours-Centre National de la Recherche Scientifique ( CNRS ), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy ( IGR ), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), hopital jean mermoz, Departement de Gastroenterologie, Clinique Turin, Departement d' endoscopie, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre d'Investigation Clinique en Biotherapie des cancers (CIC 1428 , CBT 507 ), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie [Paris], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Service d'Oncologie Médicale, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service d'Oncologie Médicale, Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: MESH : Watchful Waiting, MESH : Laparoscopy, Biopsy, MESH: Laparoscopy, MESH: Ultrasonography, Interventional, MESH : Ultrasonography, Interventional, Gastroenterology, MESH : Consensus, MESH : Tomography, Spiral Computed, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Endosonography, MESH: Biopsy, MESH: Gastrointestinal Neoplasms, 0302 clinical medicine, MESH: Practice Guidelines as Topic, Surveys and Questionnaires, Gastrointestinal Neoplasms, GiST, medicine.diagnostic_test, MESH : Gastrointestinal Stromal Tumors, MESH : Questionnaires, Gastrointestinal stromal tumours, 3. Good health, MESH: Watchful Waiting, MESH : Practice Guidelines as Topic, 030220 oncology & carcinogenesis, MESH : Endosonography, Practice Guidelines as Topic, 030211 gastroenterology & hepatology, France, MESH: Gastrointestinal Stromal Tumors, medicine.medical_specialty, Consensus, Gastrointestinal Stromal Tumors, Stromal tumours, MESH : Gastrointestinal Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Endoscopic ultrasonography, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH: Consensus, MESH : France, Watchful Waiting, Ultrasonography, Interventional, MESH: Endosonography, MESH: Humans, Hepatology, business.industry, General surgery, MESH: Questionnaires, MESH : Humans, Expert consensus, Endoscopy, MESH: France, MESH : Biopsy, Laparoscopy, MESH: Tomography, Spiral Computed, business, Tomography, Spiral Computed
Abstract: International audience; A number of guidelines on the management of gastro-intestinal stromal tumours (GISTs) have been published, mostly based on expert consensus. However, these guidelines have generally failed to address the specific problem of GISTs of limited size (i.e. those measuring a few centimetres in diameter) with which gastroenterologists are increasingly confronted. The aim of the present work was to draw up proposals for the diagnosis and treatment of GISTs measuring less than 5 cm in diameter. For this purpose, a number of practical questions were put to a panel of French experts.
Published: 2010

91. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection

Author: Dominique Salmon, Philippe Halfon, P. Perré, Guillaume Penaranda, Isabelle Fouchard-Hubert, Pascal Veillon, Laurence Weiss, Christian Michelet, Paul Calès, Patrice Cacoub, Dominique Guyader, Dominique Batisse, Jérôme Lambert, Fabrice Carrat, Louis d’Alteroche, Département d'hépato-gastroentérologie, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ) -PRES Université Nantes Angers Le Mans ( UNAM ), Laboratoire HIFIH, PRES Université Nantes Angers Le Mans ( UNAM ) -IFR132-UPRES 3859, Laboratoire Alphabio, Laboratoire alphabio, Service d'immunologie, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Epidémiologie des maladies infectieuses et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Internal Medicine Department, CHG, CHG, Microenvironnement et remodelage, Centre Hospitalier Universitaire [Rennes]-Foie, métabolismes et cancer, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Département d'hépatologie, CHRU Tours, Service des maladies infectieuses et réanimation médicale, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou, Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Biologie et thérapeutique des pathologies immunitaires ( BTPI ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Service d'immunologie [HEGP, Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Biologie et thérapeutique des pathologies immunitaires (BTPI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Liver Cirrhosis, Male, FIBROMETER, Biopsy, MESH : Prospective Studies, HIV Infections, MESH: Comorbidity, Comorbidity, Chronic liver disease, Gastroenterology, MESH: Biopsy, 0302 clinical medicine, MESH : Female, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, MESH: Prothrombin, education.field_of_study, Hematologic Tests, MESH: Middle Aged, medicine.diagnostic_test, Hepatitis C virus, Human immunodeficiency virus, MESH : Hematologic Tests, Hepatitis C, MESH: HIV Infections, Middle Aged, Diagnostic test, MESH : Adult, 3. Good health, MESH: Reproducibility of Results, Liver, Liver biopsy, MESH : Comorbidity, Female, Prothrombin, 030211 gastroenterology & hepatology, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Liver Cirrhosis, MESH : Sensitivity and Specificity, Blood test, Adult, medicine.medical_specialty, MESH : Male, Population, Liver fibrosis, Sensitivity and Specificity, MESH : Aspartate Aminotransferases, MESH: Hematologic Tests, 03 medical and health sciences, MESH: Aspartate Aminotransferases, MESH : alpha-Macroglobulins, Internal medicine, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, medicine, MESH : HIV Infections, Humans, MESH : Liver Cirrhosis, alpha-Macroglobulins, MESH : Middle Aged, Aspartate Aminotransferases, education, MESH: Hepatitis C, Metavir staging, MESH: Humans, Hepatology, business.industry, FibroTest, MESH: alpha-Macroglobulins, MESH : Reproducibility of Results, MESH : Humans, MESH: Biological Markers, Reproducibility of Results, MESH : Liver, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: ROC Curve, MESH : Prothrombin, MESH : Hepatitis C, medicine.disease, MESH: Male, MESH: Prospective Studies, MESH: Sensitivity and Specificity, MESH : Biological Markers, ROC Curve, MESH : Biopsy, Immunology, business, MESH: Female, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, MESH : ROC Curve, MESH: Liver
Abstract: International audience; BACKGROUND & AIMS: We compared 5 non-specific and 2 specific blood tests for liver fibrosis in HCV/HIV co-infection. METHODS: Four hundred and sixty-seven patients were included into derivation (n=183) or validation (n=284) populations. Within these populations, the diagnostic target, significant fibrosis (Metavir F > or = 2), was found in 66% and 72% of the patients, respectively. Two new fibrosis tests, FibroMeter HICV and HICV test, were constructed in the derivation population. RESULTS: Unadjusted AUROCs in the derivation population were: APRI: 0.716, Fib-4: 0.722, Fibrotest: 0.778, Hepascore: 0.779, FibroMeter: 0.783, HICV test: 0.822, FibroMeter HICV: 0.828. AUROCs adjusted on classification and distribution of fibrosis stages in a reference population showed similar values in both populations. FibroMeter, FibroMeter HICV and HICV test had the highest correct classification rates in F0/1 and F3/4 (which account for high predictive values): 77-79% vs. 70-72% in the other tests (p=0.002). Reliable individual diagnosis based on predictive values > or = 90% distinguished three test categories: poorly reliable: Fib-4 (2.4% of patients), APRI (8.9%); moderately reliable: Fibrotest (25.4%), FibroMeter (26.6%), Hepascore (30.2%); acceptably reliable: HICV test (40.2%), FibroMeter HICV (45.6%) (p or =F1, > or =F2) with an overall accuracy of 93% vs. 79% (p
Published: 2010

92. Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration

Author: Véronique Hofman, Paul Hofman, Valérie Vouret-Craviari, Bernard Ferrua, Robert J. Unwin, Patrick Brest, Franck Galland, Sandrine Marchetti, Annabelle Cesaro, Baharia Mograbi, Philippe Naquet, Scott S.P. Wildman, Alain Doglio, Xavier Hébuterne, Infection bactérienne, inflammation, et carcinogenèse digestive, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Laboratoire de Pathologie Clinique et Expérimentale, Centre Hospitalier Universitaire de Nice (CHU Nice), Hépato-Gastroentérologie, Royal Free and University College Medical School, Center for Nephrology, Groupe de Recherche en Immunopathologie de la Leishmaniose, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre méditérannéen de médecine moléculaire (C3M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Equipe labellisée Ligue contre le Cancer, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Immunité muqueuse et vaccination, Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Time Factors, Physiology, Neutrophils, Neutrophile, Biopsy, Interleukin-1beta, MESH: Chemotaxis, Leukocyte, MESH: Neutrophils, Severity of Illness Index, MESH: Biopsy, 0302 clinical medicine, Adenosine Triphosphate, MESH: Interleukin-1beta, MESH: Caspase 1, MESH: Adenosine Triphosphate, Intestinal Mucosa, 0303 health sciences, Crohn's disease, MESH: Receptors, Purinergic P2X7, MESH: N-Formylmethionine Leucyl-Phenylalanine, Purinergic receptor, Caspase 1, Gastroenterology, Immunohistochemistry, N-Formylmethionine Leucyl-Phenylalanine, Chemotaxis, Leukocyte, medicine.anatomical_structure, Neutrophil Infiltration, MESH: Epithelial Cells, 030220 oncology & carcinogenesis, MESH: Intestinal Mucosa, [SDV.IMM]Life Sciences [q-bio]/Immunology, RNA Interference, medicine.symptom, Inflammation Mediators, MESH: Tissue Array Analysis, tissues, RM, MESH: Enzyme Activation, MESH: Cell Line, Tumor, MESH: RNA Interference, MESH: Inflammation Mediators, Inflammation, Biology, Transepithelial Migration, digestive system, 03 medical and health sciences, Physiology (medical), Cell Line, Tumor, MESH: Severity of Illness Index, medicine, Humans, MESH: Receptors, Purinergic P2, RNA, Messenger, 030304 developmental biology, MESH: RNA, Messenger, Innate immune system, MESH: Humans, Hepatology, Receptors, Purinergic P2, MESH: Time Factors, Epithelial Cells, MESH: Immunohistochemistry, medicine.disease, Inflammatory Bowel Diseases, MESH: Inflammatory Bowel Diseases, Molecular biology, Epithelium, digestive system diseases, Enzyme Activation, MESH: Neutrophil Infiltration, Apoptosis, Tissue Array Analysis, Immunology, Receptors, Purinergic P2X7
Abstract: Inflammatory bowel diseases (IBD) are characterized during their active phase by polymorphonuclear leukocyte (PMNL) transepithelial migration. The efflux of PMNL into the mucosa is associated with the production of proinflammatory cytokines and the release of ATP from damaged and necrotic cells. The expression and function of purinergic P2X7receptor (P2X7R) in intestinal epithelial cells (IEC) and its potential role in the “cross talk” between IEC and PMNL have not been explored. The aims of the present study were 1) to examine P2X7R expression in IEC (T84 cells) and in human intestinal biopsies; 2) to detect any changes in P2X7R expression in T84 cells during PMNL transepithelial migration, and during the active and quiescent phases of IBD; and 3) to test whether P2X7R stimulation in T84 monolayers can induce caspase-1 activation and IL-1β release by IEC. We found that a functional ATP-sensitive P2X7R is constitutively expressed at the apical surface of IEC T84 cells. PMNL transmigration regulates dynamically P2X7R expression and alters its distribution from the apical to basolateral surface of IEC during the early phase of PMNL transepithelial migration in vitro. P2X7R expression was weak in intestinal biopsies obtained during the active phase of IBD. We show that activation of epithelial P2X7R is mandatory for PMNL-induced caspase-1 activation and IL-1β release by IEC. Overall, these changes in P2X7R function may serve to tailor the intensity of the inflammatory response and to prevent IL-1β overproduction and inflammatory disease.
Published: 2010

93. [Management of muscle and nerve biopsies: expert guidelines from two French professional societies, Société française de myologie et de l'Association française contre les myopathies] : Prise en charge des biopsies musculaires et nerveuses. Recommandations formalisées d'experts sous l'égide de la Société française de neuropathologie, de la Société française de myologie et de l'Association française contre les myopathies

Author: Uro-Soste, E., Fernandez, C., Authier, François-Jérôme, Bassez, G., Butori, C., Chapon, F., Delisle, M.-B., Dubourg, O., Feasson, L., Gherardi, R., Lacroix, C., Laquerriere, A., Letournel, F., Magy, Laurent, Maisonobe, T., Marcorelles, Pascale, Maurage, C.-A., Mezin, P., Mussini, J.-M., Penisson-Besnier, I., Romero, N.-B., Streichenberger, N., Vallat, Jean-Michel, Viennet, G., Vital, A., Voit, T., Boucharef, W., Figarella-Branger, D., Renseigné, Non, Service d'anatomie pathologique et histologie-cytologie [Rangueil], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Centre de référence des maladies rares neuromusculaires Aquitaine-Grand Sud Ouest, Service d'anatomie pathologique et de neurophatologie, Assistance Publique - Hôpitaux de Marseille (APHM)-CHU Marseille, Centre de référence des maladies rares neuromusculaires, INSERM U955, équipe 10, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre de référence des maladies rares neuromusculaires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de pathologie clinique et expérimentale, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de compétences pathologies neuromusculaires [CHU Caen], Thérapie des maladies du muscle strié, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de physiologie clinique, unité de myologie, CHU Saint-Etienne, Centre de référence des neuropathies amyloïdes et autres neuropathies rares, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Laboratoire de neuropathologie, Service d'Anatomie et Cytologie Pathologique [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de Pathologie Cellulaire et Tissulaire, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Laboratoire de Neurobiologie et Neuropathologie, Service de Neurologie [CHU Limoges], CHU Limoges, Biomolécules Thérapies anti-tumorales (EA4021), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Centre de référence national neuropathies périphériques rares [CHU Limoges], Service d'Anatomomie pathologique, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre de compétence des maladies rares neuromusculaires, Service d'anatomie pathologique, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département d'anatomie et cythologie pathologique, CHU Grenoble-Hôpital Michallon, CHU Grenoble, Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de neurologie [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), Service de pathologie et neuropatologie, Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Estrogènes, Expression génique et pathologies du Système Nerveux Central - UFC (E2SNC / ESTROGENES), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Bordeaux [Bordeaux], Service des actions médicales, paramédicales et psychologiques, Association Française contre les Myopathies, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], IMRB - 'Biologie du système neuromusculaire' [Créteil] (U955 Inserm - UPEC), École nationale vétérinaire - Alfort (ENVA)-Institut Mondor de Recherche Biomédicale (IMRB), Centre de référence des maladies rares neuromusculaires [CHU Pitié-Salpétriêre], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Reference des Maladies Neuromusculaires - Atlantique Occitanie Caraïbe (CRMN - AOC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)
Subjects: MESH: Muscle, Skeletal, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH: Paraffin Embedding, MESH: Immunohistochemistry, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Peripheral Nerves, MESH: Biopsy, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], MESH: Fixatives, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Glutaral, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2010

94. μ-Opioid Receptor Is Induced by IL-13 within Lymph Nodes from Patients with Sézary Syndrome

Author: Jérôme Boué, Pierre Cavaillès, Laurence Lamant, Alan Bénard, Emmanuelle Chapey, Gilles Dietrich, Jagadeesh Bayry, Nicolas Meyer, Srini V. Kaveri, Catherine Blanpied, Pierre Brousset, Centre de Physiopathologie de Toulouse-Purpan (INSERM U563 - CNRS UMR1037), Centre National de la Recherche Scientifique (CNRS)-Centre de lutte contre le cancer (CLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut Claudius Regaud, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de Recherche des Cordeliers (CRC), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], CHU Toulouse [Toulouse]-Institut Claudius Regaud-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de lutte contre le cancer (CLCC)-Centre National de la Recherche Scientifique (CNRS), IFR150, Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Sorbonne Paris Cité (USPC), Institut National de la Santé et de la Recherche Médicale (INSERM), Bisanz, Cordelia, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut Claudius Regaud-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de lutte contre le cancer (CLCC)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Dermatologie [CHU Toulouse], Pôle Clinique des Voies respiratoires [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche-Santé (Université Pierre et Marie Curie), Centre de Physiopathologie Toulouse Purpan (ex IFR 30 et IFR 150), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR30-IFR150-Institut National de la Santé et de la Recherche Médicale ( INSERM ), IFR150 ( Université Paul Sabatier ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] ( LAPM ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Centre National de la Recherche Scientifique ( CNRS ), Université Joseph Fourier - Grenoble 1 ( UJF ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Unité Mixte de Recherche-Santé ( Université Pierre et Marie Curie ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Departement of Dermatology ( CHU Purpan ), CHU Purpan, Service d'anatomie et cytologie pathologiques [Purpan], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre de Recherche en Cancérologie de Toulouse ( CRCT ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Service d'anatomie pathologique et histologie-cytologie [Rangueil], and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil
Subjects: CD4-Positive T-Lymphocytes, MESH: Interleukin-13, Skin Neoplasms, MESH : RNA, Messenger, Enkephalin, Biopsy, Receptors, Opioid, mu, Gene Expression, MESH: Lymph Nodes, CD8-Positive T-Lymphocytes, MESH: Monocytes, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, Biochemistry, Monocytes, MESH: Biopsy, 0302 clinical medicine, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, Opioid receptor, polycyclic compounds, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Receptor, Lymph node, Cells, Cultured, MESH : Lymph Nodes, ComputingMilieux_MISCELLANEOUS, Endogenous opioid, MESH: Langerhans Cells, 0303 health sciences, Interleukin-13, MESH : Receptors, Opioid, mu, MESH: Dendritic Cells, MESH : Immune Tolerance, MESH: CD4-Positive T-Lymphocytes, MESH : CD8-Positive T-Lymphocytes, MESH: CD8-Positive T-Lymphocytes, 3. Good health, medicine.anatomical_structure, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH : CD4-Positive T-Lymphocytes, MESH: Sezary Syndrome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Lymph, MESH: Cells, Cultured, MESH: Gene Expression, MESH: Immune Tolerance, [SDV.IMM] Life Sciences [q-bio]/Immunology, medicine.drug_class, MESH : Langerhans Cells, MESH: Receptors, Opioid, mu, Dermatology, Biology, 03 medical and health sciences, Immune system, MESH : Cells, Cultured, MESH : Interleukin-13, mental disorders, Immune Tolerance, medicine, Humans, Sezary Syndrome, RNA, Messenger, Opioid peptide, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, Molecular Biology, 030304 developmental biology, MESH: RNA, Messenger, MESH : Sezary Syndrome, MESH: Humans, MESH: Skin Neoplasms, MESH : Skin Neoplasms, MESH : Humans, Dendritic Cells, Cell Biology, MESH : Gene Expression, MESH : Monocytes, nervous system, Langerhans Cells, MESH : Biopsy, MESH : Dendritic Cells, Immunology, Lymph Nodes, human activities, 030215 immunology
Abstract: International audience; Endogenous opioid peptides mainly produced by neurons are also released by immune cells. They bind to mu- (mu-opioid receptor, MOR), delta-, and kappa-opioid receptors. On the basis of studies on mice showing that MOR is the main mediator of the deleterious effects of opioids on immunity, we wondered whether MOR, absent under normal conditions, is expressed in some pathological situations such as lymphomas. mRNA expression for all three opioid receptors was examined in lymph node biopsy samples from patients with non-Hodgkin's B-cell and T-cell lymphomas. We found that MOR and one of its ligands (enkephalin) are simultaneously expressed almost exclusively in lymph nodes from patients with Sézary cutaneous T cell lymphoma. As MOR was undetectable in circulating malignant T lymphocytes and in normal immune cells, we hypothesized that tumor-released cytokines might induce MOR expression in non-neoplastic lymph node cells. The correlation between mRNA levels of MOR and interleukin-13 (IL-13) within lymph nodes from Sézary patients led us to investigate the ability of IL-13 to upregulate MOR expression in normal immune cell subsets. We found that IL-13 upregulates MOR in activated Langerhans cells. Thus, our data suggest that, under pathological conditions, IL-13 overexpression might allow immune-derived endogenous opioids to down-modulate immune response.
Published: 2010

95. Atypical presentation of adult T-cell leukaemia/lymphoma due to HTLV-1: prurigo nodularis lasting twelve years followed by an acute micropapular eruption

Author: Olivier Cassar, Antoine Petit, Isabelle Moulonguet, Jacqueline Rivet, Antoine Gessain, Daniel Wallach, Félix Agbalika, Arnaud Duval, Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anatomo-pathologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Service de Virologie, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de Dermatologie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and CHU Cochin [AP-HP]
Subjects: CD4-Positive T-Lymphocytes, Male, Pathology, MESH: Anemia, Refractory, with Excess of Blasts, Time Factors, Biopsy, MESH: Interleukin-2 Receptor alpha Subunit, Serology, 030207 dermatology & venereal diseases, MESH: Biopsy, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Medicine, Leukemia-Lymphoma, Adult T-Cell, MESH: Leukemia-Lymphoma, Adult T-Cell, Skin, MESH: Treatment Outcome, 0303 health sciences, Human T-lymphotropic virus 1, MESH: Middle Aged, MESH: CD4-Positive T-Lymphocytes, MESH: Zidovudine, General Medicine, Middle Aged, Recombinant Proteins, 3. Good health, Leukemia, Treatment Outcome, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Monoclonal, Viral disease, Zidovudine, MESH: Interferon Alfa-2a, MESH: Antiviral Agents, medicine.medical_specialty, MESH: Prurigo, Antineoplastic Agents, Dermatology, Interferon alpha-2, Antiviral Agents, Adult T-cell leukemia/lymphoma, 03 medical and health sciences, MESH: Skin, Prurigo, Humans, 030304 developmental biology, Anemia, Refractory, with Excess of Blasts, MESH: Human T-lymphotropic virus 1, MESH: Humans, business.industry, MESH: Time Factors, Interleukin-2 Receptor alpha Subunit, Interferon-alpha, medicine.disease, MESH: Male, Lymphoma, MESH: Antineoplastic Agents, business, Prurigo nodularis
Abstract: International audience; Prurigo nodularis is a pruritic dermatosis of unknown origin. Human T-cell lymphotropic virus type 1 (HTLV-1) causes adult T-cell leukaemia/lymphoma. HTLV-1 is not considered to be a cause of prurigo nodularis. A 52-year-old black man, from the French West Indies, who had had prurigo nodularis for 12 years, presented with a distinct micropapular eruption with the typical pathological picture of epidermotropic T-cell lymphoma. Based on HTLV-1-positive serology and monoclonal integration of HTLV-1 we diagnosed smouldering adult T-cell leukaemia/lymphoma. Re-examination of previous skin biopsies revealed that the disease had been evolving for 12 years. Treatment with alpha-interferon, 3 x 106 units three times a week, associated with zidovudine, 1 g daily, resulted in complete remission within 4 months. When investigating a prurigo nodularis, we therefore recommend: (i) performing HTLV-1 serology if the patient comes from an endemic area; (ii) if positive, performing CD25 staining and looking for a HTLV-1 clonal integration; and (iii) if positive, using a treatment targeting HTLV-1.
Published: 2010

96. Effect of dutasteride on the risk of prostate cancer

Author: Andriole, G.L., Bostwick, D.G., Brawley, O.W., Gomella, L.G., Marberger, M., Montorsi, F., Pettaway, C.A., Tammela, T.L.J., Teloken, C., Tindall, D.J., Somerville, M.C., Wilson, T.H., Fowler, I.L., Rittmaster, R.S., Mulders, P.F.A., Schrier, B.P., Department of urology, Università Vita-Salute San Raffaele, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Andriole Gerald, L., Bostwick David, G., Brawley Otis, W., Gomella Leonard, G., Marberger, Michael, Montorsi, Francesco, Pettaway Curtis, A., Tammela Teuvo, L., Teloken, Claudio, Tindall Donald, J., Somerville Matthew, C., Wilson Timothy, H., Fowler Ivy, L., Rittmaster Roger, S., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'urologie, andrologie et transplantation rénale, and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques
Subjects: Male, Relative risk reduction, Prostate biopsy, Biopsy, MESH : Risk, Prostatic Hyperplasia, 030232 urology & nephrology, MESH : Aged, MESH: Protein Isoforms, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Biopsy, chemistry.chemical_compound, Prostate cancer, 5-alpha Reductase Inhibitors, 0302 clinical medicine, Erectile Dysfunction, Protein Isoforms, MESH: Double-Blind Method, Enzyme Inhibitors, MESH : Prostate-Specific Antigen, 10. No inequality, MESH: Treatment Outcome, MESH: Erectile Dysfunction, MESH: Aged, MESH: Risk, MESH: Middle Aged, medicine.diagnostic_test, Prostate, General Medicine, Middle Aged, MESH : Prostatic Hyperplasia, MESH: Prostate-Specific Antigen, 3. Good health, Prostate-specific antigen, Treatment Outcome, MESH: Enzyme Inhibitors, 030220 oncology & carcinogenesis, Finasteride, medicine.symptom, MESH : Prostatic Neoplasms, Risk, medicine.medical_specialty, MESH : Male, Urology, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Testosterone 5-alpha-Reductase, MESH : Treatment Outcome, MESH: Prostate, MESH: Azasteroids, MESH: Prostatic Hyperplasia, 03 medical and health sciences, Double-Blind Method, Translational research [ONCOL 3], medicine, Humans, MESH : Double-Blind Method, MESH : Middle Aged, MESH: Testosterone 5-alpha-Reductase, Aged, MESH : Azasteroids, Heart Failure, Gynecology, MESH : Enzyme Inhibitors, MESH: Humans, MESH : Erectile Dysfunction, business.industry, Urinary retention, MESH : Humans, Prostatic Neoplasms, MESH : Protein Isoforms, Dutasteride, Prostate-Specific Antigen, medicine.disease, MESH: Male, chemistry, Azasteroids, MESH: Prostatic Neoplasms, MESH : Biopsy, MESH: Heart Failure, Prostate surgery, business, MESH : Heart Failure, MESH : Prostate
Abstract: Background: We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Methods: In this 4-year, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, we compared dutasteride, at a dose of 0.5 mg daily, with placebo. Men were eligible for inclusion in the study if they were 50 to 75 years of age, had a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng per milliliter, and had had one negative prostate biopsy (6 to 12 cores) within 6 months before enrollment. Subjects underwent a 10-core transrectal ultrasound-guided biopsy at 2 and 4 years. Results: Among 6729 men who underwent a biopsy or prostate surgery, cancer was detected in 659 of the 3305 men in the dutasteride group, as compared with 858 of the 3424 men in the placebo group, representing a relative risk reduction with dutasteride of 22.8% (95% confidence interval, 15.2 to 29.8) over the 4-year study period (P
Published: 2010

97. Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2

Author: Emilie Fréalle, Odile Mercereau-Puijalon, Hamoud O Brahim, Alioune Gaye, Laurence Marrama, Jean Marie Dangou, Jean Y. Lehesran, Demba Sarr, Makhtar Niang, Ronan Jambou, Delphine Aldebert, Institut Pasteur de Dakar, Réseau International des Instituts Pasteur (RIIP), Centre de Santé Roi Baudoin, Immunologie moléculaire des parasites, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), UR10, Mother & Child Unit, Mother & Child Unit, Santé de la mère et de l'enfant en milieu tropical : épidémiologie génétique et périnatale, Université Paris Descartes - Paris 5 (UPD5), Département de Parasitologie Mycologie, Institut Pasteur [Paris] (IP), Institut Pasteur de Dakar - Réseau International des Instituts Pasteur (RIIP), Institut Pasteur [Paris] - Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris], and Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)
Subjects: MESH: Inflammation, MESH : RNA, Messenger, Placenta Diseases, Placenta, 0302 clinical medicine, MESH: Pregnancy, Pregnancy, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH : Pregnancy Complications, Parasitic, MESH: Up-Regulation, MESH : Up-Regulation, 0303 health sciences, MESH : Reverse Transcriptase Polymerase Chain Reaction, Pregnancy Outcome, MESH: Placenta, MESH : Senegal, Immunohistochemistry, MESH: Case-Control Studies, 3. Good health, Up-Regulation, Interleukin 10, MESH : Placenta, MESH: Young Adult, MESH : Infant, Low Birth Weight, MESH : Case-Control Studies, lcsh:RC955-962, MESH : Cyclooxygenase 2, MESH : Young Adult, MESH: Infant, Low Birth Weight, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, MESH: Senegal, MESH : Adolescent, Humans, RNA, Messenger, MESH: Adolescent, MESH : Inflammation, MESH: Humans, MESH : Humans, MESH: Adult, medicine.disease, MESH : Pregnancy, MESH : Biopsy, Case-Control Studies, Immunology, Parasitology, Cyclooxygenase, MESH: Female, Malaria, MESH: Interleukin-10, MESH : Immunohistochemistry, Biopsy, MESH : Malaria, Falciparum, MESH: Pregnancy Complications, Parasitic, MESH: Placenta Diseases, MESH: Biopsy, MESH: Reverse Transcriptase Polymerase Chain Reaction, MESH : Female, Malaria, Falciparum, MESH : Pregnancy Outcome, biology, Reverse Transcriptase Polymerase Chain Reaction, MESH: Malaria, Falciparum, MESH: Infant, Newborn, MESH : Adult, Senegal, Interleukin-10, Infectious Diseases, medicine.anatomical_structure, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, medicine.symptom, MESH: Cyclooxygenase 2, Adult, lcsh:Arctic medicine. Tropical medicine, Adolescent, 030231 tropical medicine, MESH : Placenta Diseases, Inflammation, MESH : Infant, Newborn, Young Adult, MESH : Interleukin-10, medicine, lcsh:RC109-216, 030304 developmental biology, MESH: RNA, Messenger, Research, Infant, Newborn, MESH: Immunohistochemistry, Infant, Low Birth Weight, MESH: Pregnancy Outcome, Chronic infection, Cyclooxygenase 2, Pregnancy Complications, Parasitic, biology.protein
Abstract: BackgroundPlacental malaria (PM) is associated with poor foetal development, but the pathophysiological processes involved are poorly understood. Cyclooxygenase (COX) and lipoxygenase (LOX) which convert fatty acids to prostaglandins and leukotrienes, play important roles in pregnancy and foetal development. COX-2, currently targeted by specific drugs, plays a dual role as it associates with both pre-eclampsia pathology and recovery during infection. The role of COX during PM was questioned by quantifying at delivery COX-1, COX-2, 15-LOX, and IL-10 expression in two groups of malaria infected and uninfected placenta.MethodsPlacental biopsies were collected at delivery for mRNA isolation and quantification, using real time PCR.ResultsCOX-2 and IL-10 mRNAs increased mainly during chronic infections (nine- and five-times, respectively), whereas COX-1 transcripts remained constant. COX-2 over-expression was associated with a higher birth weight of the baby, but with a lower rate of haemoglobin of the mother. It was associated with a macrophage infiltration of the placenta and with a low haemozoin infiltration. In the opposite way, placental infection was associated with lower expression of 15-LOX mRNA. A high degree of haemozoin deposition correlates with low birth weight and decreased expression of COX-2.ConclusionThese data provide evidence that COX-2 and IL-10 are highly induced during chronic infection of the placenta, but were not associated with preterm delivery or low birth weight. The data support the involvement of COX-2 in the recovery phase of the placental infection.
Published: 2010

98. Renal biopsies after 70 years of age: a retrospective longitudinal study from 2000 to 2007 on 150 patients in Western France

Author: Cécile Vigneau, Patrick Le Pogamp, Thierry Frouget, Emilie Pinçon, Nathalie Rioux-Leclercq, De Villemeur, Hervé, Service de néphrologie [Rennes], Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), CHU Pontchaillou [Rennes]-Hôpital Pontchaillou-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Aging, Health (social science), Biopsy, 030232 urology & nephrology, 030204 cardiovascular system & hematology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Biopsy, 0302 clinical medicine, Elderly, therapeutics, Medicine, Longitudinal Studies, MESH: Longitudinal Studies, MESH: Aged, Kidney, MESH: Statistics, Nonparametric, medicine.diagnostic_test, Mortality rate, 3. Good health, Survival Rate, medicine.anatomical_structure, Female, Kidney Diseases, Renal biopsy, France, medicine.medical_specialty, MESH: Survival Rate, Statistics, Nonparametric, MESH: Prognosis, Nephropathy, 03 medical and health sciences, renal biopsy, Internal medicine, Humans, Survival rate, Aged, Retrospective Studies, MESH: Kidney Diseases, MESH: Humans, business.industry, Retrospective cohort study, MESH: Retrospective Studies, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, Surgery, MESH: France, prognosis, Geriatrics and Gerontology, business, Gerontology, Nephrotic syndrome, MESH: Female
Abstract: International audience; The elderly are more often referred to nephrologists and questions about indications for renal biopsy are increasing. The vascular lesions that appear with aging make the diagnosis of additional nephropathy more difficult. The purpose of our study is to investigate the characteristics of renal biopsies in the elderly in order to evaluate the indications and their use in guiding specific therapeutic interventions. Patients over 70 years who underwent a renal biopsy between 2000 and 2007 in Rennes University Hospital were retrospectively analyzed for biopsy complications, clinical features, diagnosis, therapy and its complications, evolution and mortality. Among the 150 renal-biopsied patients, 60% had a glomerulopathy and 30% had nephrotic syndrome. Biopsy complications occurred in 3.3%. 64% of nephrotic patients received immunosuppressive treatment and 62% of them developed drug-associated complications. In the treated group, there was more remission and survival at day 1000 was improved. Renal biopsy may be indicated in the elderly, because it often gives a therapeutically useful diagnosis and complications are rare if contra-indications are respected. Kidney biopsy revealed histological diagnoses that were not usually suspected by the clinical presentation. In addition, immunosuppressive therapy did not alter the mortality rate, but did increase survival at 3 years.
Published: 2010

99. [Choriocarcinoma with pulmonary metastasis: diagnosis and treatment]

Author: Olezac, A.-S., Papanikolaou, I., Bengrine-Lefevre, L., Chouaid, C., Annesi-Maesano, Isabella, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Olezac AS, je Papanikolaou, L-Lefevre Bengrine, and C Chouaid .
Subjects: MESH: Remission Induction, Antimetabolites, Antineoplastic, Lung Neoplasms, Skin Neoplasms, Biopsy, MESH: Choriocarcinoma, Non-gestational, MESH: Scalp, Chorionic Gonadotropin, MESH: Prognosis, Diagnosis, Differential, MESH: Biopsy, MESH: Skin, MESH: Chorionic Gonadotropin, MESH: Diagnosis, Differential, MESH: Liver Neoplasms, Humans, Choriocarcinoma, Skin, MESH: Antimetabolites, Antineoplastic, MESH: Middle Aged, MESH: Humans, Scalp, urogenital system, MESH: Skin Neoplasms, Liver Neoplasms, Remission Induction, Choriocarcinoma, Non-gestational, MESH: Radiography, Thoracic, Middle Aged, Prognosis, Kidney Neoplasms, MESH: Lung Neoplasms, MESH: Choriocarcinoma, Pancreatic Neoplasms, MESH: Methotrexate, Methotrexate, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, Radiography, Thoracic, MESH: Pancreatic Neoplasms, MESH: Kidney Neoplasms, MESH: Tomography, X-Ray Computed, Tomography, X-Ray Computed, MESH: Female
Abstract: International audience; INTRODUCTION: Choriocarcinoma is a rare tumour which results from the anarchic proliferation of a gonadic or extra gonadic germinal cell. CASE REPORT: A 45 year old pre menopausal woman of African origin presented with a persistent cough and deterioration of general status. The chest X-ray revealed a cavitated mass of the right upper lobe. Other lesions were associated (liver, kidney and scalp). Choriocarcinoma, suspected in the presence of an elevated ssHCG without a gravid uterus, was confirmed by biopsy excision of a haemorrhagic cutaneous lesion of the scalp. Despite the poor prognosis methotrexate based chemotherapy resulted in control of the disease and a good remission.
Published: 2009

100. [Etiological assessment of cerebral infarct in the young. Proposals from the working group of the French Neuro-vascular Society (December 2008)] : Bilan étiologique des infarctus cérébraux du sujet jeune. Propositions du Groupe de travail de la Société française neuro-vasculaire (décembre 2008)

Author: Rouanet, François, Sibon, I., Goizet, C., Renou, P., Meissner, W., Renseigné, Non, Macian-Montoro, Francisco, Al., Et, Université Sciences et Technologies - Bordeaux 1, Groupe de travail de la Société française neuro-vasculaire, Société française neuro-vasculaire, Service de Neurologie [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), and Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges (UNILIM)
Subjects: MESH: Middle Aged, MESH: Humans, MESH: Cerebral Angiography, MESH: Societies, Medical, MESH: Adult, MESH: Electrocardiography, MESH: Magnetic Resonance Imaging, MESH: France, MESH: Biopsy, MESH: Cerebral Infarction, MESH: Echocardiography, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH: Heart Rate, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2009

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

175 results on '"MESH: Biopsy"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources